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Summary 
Oropharyngeal Candidiasis (OPC) is an opportunistic fungal infection that affects 
mostly infants and immunocompromised patients. In recent years, the disease has 
been on the rise due to an increased life span, the HIV pandemic and the increased 
use of broad spectrum antibiotics. OPC may be treated using a nystatin suspension, 
which is not as effective as it could be due to the mechanism by which the suspension 
is applied to the affected tissue. This research aims to improve the effectiveness of 
nystatin, for the treatment of OPC, by proposing a nystatin loaded micellar system 
incorporated into a mucoadhesive system for drug delivery. This will ensure that 
nystatin is gradually released from the film, thus increasing retention time of nystatin 
at the affected area. 
In this study, a mixture design was developed, which was used to determine the most 
appropriate solvent system for nystatin solubilization. Optimisation of the micelle 
formulation was achieved by using the central composite rational design (CCRD). The 
two factors that were taken into consideration were the temperature of the hydration 
medium (water) and the length of time the micellar solution was exposed to the 
temperature environment of the rotary evaporator. The responses that were 
investigated were the mean particle size, mean polydispersity index (PDI), mean zeta 
potential, change in mean particle size and change in mean PDI. The optimal micelle 
formulation was characterised for size, stability, morphology and drug encapsulation 
efficiency. The micelles were found to be spherical and stable with an acceptable size 
range. However, their drug encapsulation efficiency was low. 
The mucoadhesive film was formulated and characterised for physical characteristics, 
pliability, percentage swelling index and drug release profile. The film was found to be 
highly pliable and evenly distributed with a smooth surface; no bumps or bubbles were 
visible. The film was able to swell to up to 550 %. In vitro studies showed that nystatin 
was gradually released from the film. 
 Key words: central composite rotational design, mucoadhesive film, oropharyngeal 
candidiasis, polymeric micelles, response surface methodology 
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CHAPTER 1 
Introduction 
1.1 Background 
Oropharyngeal candidiasis (OPC) is known to be one of the most common 
opportunistic infections affecting humans. It is caused by a Candida species known as 
Candida albicans (Darwazeh & Darwazeh, 2014). OPC predominantly affects infants, 
diabetic patients, patients using broad-spectrum antibiotics and those with a 
compromised immune system. In South Africa, OPC is treated using a topically applied 
nystatin suspension (Department of Health, 2013). Due to its mechanism of 
application, the topical agent is not very effective which results in high instances of 
recurrence and treatment failure (Garcia-Cuesta et al.,  2014). According to Thompson  
and colleagues (2010), relapse of OPC is more prevalent in patients who were treated 
using topical agents (Thompson et al., 2010). OPC has received attention due to its 
increased prevalence which is reflective of the HIV/AIDS pandemic; the increase in 
invasive medical practices; an increase in the use of broad-spectrum antibiotics and 
immunosuppressive therapies (D. Williams & Lewis, 2011); as well as an increase in 
conditions such as diabetes and malnutrition (Patil et al., 2015). 
The discovery of a new drug is a time consuming and expensive exercise, but is of 
utmost importance to develop novel methods that aid in overcoming the limitations 
associated with everyday drug use (Tiwari et al., 2013). The institution of a minor 
change to a drug that may not have been effective in its original dosage form, such as 
a change in the dosage form, may lead to increased efficacy, bioavailability and 
effectiveness of the drug (Rangasamy & Parthiban, 2010). Nystatin is one such drug 
that requires a change in dosage form. Although nystatin is used often, it is not as 
efficacious as it could be due to its dosage form and mechanism of administration 
(Garcia-Cuesta et al., 2014). Nystatin’s current dosage form for treatment of OPC is 
in the form of a suspension, which does not have the ability to adhere to the affected 
parts of the mucosa. Nystatin is administered orally, using a dropper to accurately take 
up the recommended dose. The patient uses the dropper to drop the drug near or unto 
the affected area. Once the drug is in the patient’s mouth, they are required to swirl 
the suspension in their mouth and keep it in their mouth for as long as possible before 
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it may be either spat out or swallowed (South African Department of Health, 2013). 
This mechanism of application is difficult to implement in infants and severely ill 
patients. By changing the dosage form to one that is capable of penetrating into the 
inflamed tissues and adhering to the mucosa, it may be possible to improve the 
therapeutic outcome.  
A technology that aids in an improved drug delivery system is nanotechnology. 
According to Singh and Lillard (2009) nanotechnology allows for the synthesis, 
manipulation, study and characterization of structures and devices that are within the 
nanometer range, known as nanomaterials or nanoparticles. Advantages associated 
with nanomaterials include increased solubility of a highly insoluble drug, controlled 
drug release and the ability of nanomaterials to only accumulate in the inflamed tumour 
tissue; this occurrence is known as the permeation and retention effect (Singh & 
Lillard, 2009). It is important for nystatin to have the ability to adhere to the mucosa so 
as to prevent saliva from washing the drug away. In order for nystatin to be effective it 
needs to be in contact with the affected area for as long as possible. One way to 
ensure that nystatin is in constant contact with the mucosa and to minimise the 
chances of the drug being washed away by saliva is to use a mucoadhesive system 
(Jin et al., 2018). Mucoadhesion is the adhesion between the mucosal surface and the 
surface of another material. The advantage of using a mucoadhesive system is that it 
allows for slow release of the drug and increases the retention time of the drug in the 
affected area (Donnelly et al., 2011; Sabry, 2018). 
1.2 Problem Statement 
The problems associated with the use of nystatin oral suspension stem from the 
dosage form not having the capability to adhere to the mucosa, thus decreasing 
contact time of the drug with the affected area. This results in the drug not being as 
effective as it could be (Garcia-Cuesta et al., 2014). Other disadvantages associated 
with the use of the suspension include a decrease in patient compliance due to the 
unpleasant taste; and the high frequency of administration, since the suspension 
needs to be applied four times a day (Thompson et al., 2010). Some nystatin 
suspension formulations have high levels of sucrose and ethanol which are used to 
mask the bitter taste of nystatin. The ethanol may cause local irritation and the sucrose 
may lead to tooth decay and cause unwanted side effects in diabetic patients (Campos 
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et al., 2012). This study proposes the development of a nystatin-loaded micellar 
system which will be incorporated into a mucoadhesive film. This allows for longer 
contact time with the affected area, therefore successfully dealing with the controlled 
release of the drug to the affected area. The discovery of a new and innovative way to 
change the dosage form and the mechanism of administration of nystatin oral 
suspension may make the treatment of OPC easier on patients and caregivers. The 
ease of care will be experienced as a by-product of the lower dosing frequency and 
the ease of application of the new innovative film. This may combat the issue of high 
frequency of treatment failure and recurrence, due to low patient compliance and a 
poor mechanism of administration (Garcia-Cuesta et al., 2014). 
1.3 Aim and Objectives  
1.3.1 Aim. 
The aim of this study is to develop a buccal mucoadhesive film containing nystatin 
encapsulated in a polymeric micelle. This is proposed for the treatment of 
oropharyngeal candidiasis in children and chronically ill patients. 
1.3.2 Objectives. 
Based on the aim outlined above, the proposed objectives are as follows: 
1. Determination of the most appropriate solvent system for solubilizing nystatin 
using a statistical methodology. 
2. Formulation of a polymeric micellar system containing nystatin. 
3. Characterisation of the micellar system with respect to particle size and the 
physical stability, morphology and drug encapsulation efficiency. 
4. Formulation of a mucoadhesive film with the incorporated micellar system. 
5. Characterisation of the mucoadhesive film with respect to physical 
characteristics, mechanical strength swelling index and surface pH.           
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CHAPTER 2 
Literature Review 
2.1 Oropharangeal Candidiasis (OPC) 
2.1.1 Introduction. 
OPC can be described as a common opportunistic fungal infection often caused by 
Candida albicans of the Candida species (Pankhurst, 2009). In a healthy human, there 
are small amounts of Candida present in the oral cavity, skin and the digestive tract, 
that form part of the normal microflora. Candida, present in small amounts must 
compete with other microorganisms in the body, including bacteria for nutrition and 
space. When there is an imbalance in the microflora due to factors such as antibiotic 
use, chronic illness affecting the immune system, as well as medications that alter 
hormones in the body, the Candida opportunistically becomes a pathogen, thus 
causing what is known as OPC in the patient (Darwazeh & Darwazeh, 2014; Pietrzak 
et al., 2018). 
The prevalence of OPC varies with the age and strength of immunity of the patient, as 
well as the medication that the patient may be taking (Akpan & Morgan, 2002). It is 
agreed upon that immunocompromised patients such as those suffering from cancer 
and those infected with the HIV/AIDS, diabetic patients, patients who wear dentures, 
young children and patients using medications such as corticosteroids, antibiotics and 
contraceptives are at a higher risk of developing OPC (Akpan & Morgan, 2002; 
Asmarawati et al., 2018; Campinha-Bacote et al., 2002; Pankhurst, 2009; Patil et al., 
2015; World Health Organisation, 2014). Garcia-Cuesta and colleagues (2014) found 
that OPC has been prevalent in the developed countries over the last decade. The 
authors attribute this to a lengthened life span, extended duration of antibiotic use, the 
use of dentures, endocrine disorders and dry mouth (Vincent, 2001; Garcia-Cuesta et 
al., 2014; Williams & Lewis, 2011). OPC has a high frequency of recurrence and 
treatment failure. This may be attributed to failure by the health care practitioner to 
identify the underlying condition, thereby putting a patient at risk of OPC, by incorrectly 
diagnosing the patient, or the patient being prescribed the incorrect antifungal agent 
for OPC treatment (Darwazeh & Darwazeh, 2014). 
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2.1.2 The different forms of OPC infections. 
Garcia-Cuesta and colleagues (2014) state that OPC may clinically manifest in four 
different forms, namely: pseudomembranous thrush, erythematous thrush, 
hyperplastic thrush and Candida-associated lesions. Some of the general symptoms 
associated with OPC include white films in the mouth, altered taste, painful mouth, 
and a burning sensation on the tongue. These symptoms may result in a general 
decrease in the quality of life of the patient, as they experience a decline in nutritional 
intake due to an unwillingness to eat or drink, as well as impaired speech due to the 
pain associated with the condition (Akpan & Morgan, 2002). 
Pseudomembranous thrush is characterized by white plaque found in the throat, on 
the tongue, gingiva and the buccal mucosa, which on removal results in painful red 
films where the plaque was. This type of OPC is observed in children, 
immunocompromised patients as well as patients on corticosteroids. Erythematous 
thrush is mostly associated with the lengthened use of broad-spectrum antibiotics and 
is characterized by the presence of smooth red films on the soft and hard palate, 
buccal mucosa and on the dorsum of the tongue (Patil et al., 2015). Erythematous 
thrush is seen chronically in HIV/AIDS patients, with this type of OPC often being 
painful. Hyperplastic thrush is characterized by white plaques which are firmly bound 
to the buccal mucosa, tongue and palates in a bilateral manner. The plaques, in this 
case, cannot be removed and this form of OPC is seen most commonly in patients 
who smoke (D. Williams & Lewis, 2011). The different manifestations of OPC are 
shown in Figures  2.1 and 2.2. 
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Figure 2. 1: The different manifestation of Oropharyngeal Candidiasis (Shinde, 
2016)  
2.1.3 Candida associated lesions. 
There are many different forms of Candida-associated lesions, for example denture 
stomatitis, linear gingival erythema and angular cheilitis. Denture stomatitis is 
characterized by the presence of granular or smooth films on the hard palate of the 
area where the dentures were being worn. This form of thrush is also associated with 
angular cheilitis and only affects patients who wear dentures (Patil et al., 2015). Linear 
gingival erythema is associated with HIV/AIDS infected patients. This type of OPC is 
observed as a linear band of red inflamed tissue, about 2-3 mm long, found on the 
marginal gingiva. It is caused by Candida albicans and/or Candida dubliniensis, both 
of which belong to the Candida family (D. Williams & Lewis, 2011). Angular cheilitis 
mostly affects patients who have been wearing dentures for a long time and those with 
iron and vitamin B12 deficiency. It is characterized by small red and inflamed tears in 
the corners of the mouth (Akpan & Morgan, 2002). Table 2.1 summarises the different 
manifestations of OPC while outlining the patients that are most at risk of the different 
manifestations. 
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Denture Stomatitis Linear gingival erythema 
Figure 2. 2: Clinical manifestations of Candida-associated lesions (Shinde, 2016) 
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Table 2. 1: The different manifestations of Oropharyngeal Candidiasis 
 
OPC Manifestation 
type  
Characterization Patients mostly at risk 
Pseudomembranous 
thrush 
White plaque in the throat, on the 
tongue, gingiva and the buccal 
mucosa.  
Children, patients on 
corticosteroids, 
contraceptives, diabetic 
patients and 
immunocompromised 
patients. 
Erythematous thrush Painful, smooth red films found on the 
soft and hard palate, buccal mucosa 
and on the dorsum of the tongue.  
Patients on prolonged 
treatment of antibiotics 
and HIV/AIDS patients. 
Hyperplastic thrush  White plaque firmly bound to the 
tongue, buccal mucosa and palates in 
a bilateral manner.  
Smokers. 
Candida Associated lesions 
Denture stomatitis Presence of granular or smooth films 
on the hard palate of the area where 
the dentures were being worn.  
Denture wearing 
patients. 
Linear gingival 
erythema  
Presence of red inflamed gums which 
may be bleeding. 
HIV/AIDS infected 
patients.  
Angular cheilitis Presence of red and inflamed tears in 
the corners of the mouth.   
Denture wearing 
patients, Geriatric 
patient, Iron and Vitamin 
B12 deficient patients. 
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2.1.4 Treatment of OPC. 
OPC can be treated successfully using antifungal agents in healthy individuals when 
it is a primary infection. In patients who experience OPC as a secondary infection, the 
primary cause needs to be addressed before treatment will be successful. It is of 
clinical importance to know the lifestyle of the patient so that the it may be accurately 
diagnosed. This will aid in identification of the underlying cause of the OPC and thus 
the treatment choice. If the primary cause is not identified, the OPC infection will recur 
regardless of how well it has been treated (Garcia-Cuesta et al., 2014). Once the 
primary cause has been identified, the correct rectifying action can be taken, be it a 
lifestyle or drug intervention. OPC is usually treated using local antifungal agents such 
as nystatin, miconazole and clotrimazole (Rossiter, 2014). Medications that are used 
for the treatment of oral thrush are available in the form of tablets, liquids, gels and 
lozenges.  
According to Rossiter (2014), there are systemic drugs available for the treatment of 
OPC such as fluconazole and itraconazole. The systemic drugs may be used in 
complicated cases of OPC where the patient does not respond to topical treatment. 
Even though the systemic drugs have been proven to work better than nystatin, they 
are susceptible to numerous drug interactions, and adverse effects which limits their 
use in the treatment of topical infections(Lyu et al., 2016).  
Although miconazole and nystatin are both local antifungal agents, nystatin is superior 
to miconazole, because about 17% of Candida species have developed resistance to 
miconazole (Collins, Cookinham, & Smith, 2011). This sometimes results in cross-
resistance to other azoles such as fluconazole (Campos et al., 2012), while no 
resistance has been developed by Candida albicans to nystatin. Miconazole also has 
the disadvantage of interacting with other drugs. The major drug interaction to note 
with topical miconazole use, is that when used simultaneously with warfarin there is a 
chance of haemorrhaging (Rossiter, 2014). There are no major drug interactions 
associated with topical use of nystatin. Miconazole is also absorbed by the intestine 
which promotes hepatotoxicity as a side effect (Garcia-Cuesta et al., 2014). Other 
agents that can be used to treat OPC but are not considered to be antifungal agents 
include chlorhexidine mouth wash and gentian violet (Rossiter, 2014).  
  
 
10
Nystatin is administered orally by instilling 1 ml - 2 ml of the suspension into the mouth 
every four hours. Nystatin pessaries may be used off-label to be sucked on as a 
lozenge four times a day (Rossiter, 2014). The problem associated with the first line 
treatment is its bitter taste and frequency of administration, which decreases patient 
compliance. The nystatin suspension does not adhere well to the mucous membrane, 
thereby impairing its efficacy, as most of the drug is washed away by saliva (Garcia-
Cuesta et al., 2014). 
For more severe cases, fluconazole in a dose of 200 mg is taken orally for 14 days. 
Fluconazole is an azole antifungal agent and works by preventing lanosterol from 
being converted into ergosterol which is an essential component of the fungal cell 
membrane. This results in an increased permeability of the fungal cell leading to a 
leakage of the cell contents, thereby killing the fungal cell (Katzung et al., 2012). Some 
side effects associated with fluconazole include nausea, vomiting, abdominal pain and 
skin rash. Fluconazole interacts with any drug that is metabolized by cytochrome P450 
enzymes, as it is a weak inhibitor of the enzyme (Rossiter, 2014). Fluconazole will 
inhibit their metabolism thus increasing the drug’s half-life. 
Chlorhexidine is a disinfectant and a broad-spectrum antiseptic agent that may be 
used in the treatment of OPC and any other superficial gingival infection. For the 
treatment of OPC, chlorhexidine is used as a mouth wash where the patient would use 
15 ml to 30 ml to gargle and spit out every four hours. Some of the side effects 
associated with chlorhexidine include discoloration of the tongue and surface enamel 
(Rossiter, 2014).  
Gentian violet is an antiseptic dye used for the treatment of fungal infections. In OPC, 
gentian violet is used by painting it onto the oral mucosa at least three times a day. 
The problem associated with this treatment is the discoloration of the mouth is not 
accepted by most patients. Side effects associated with this treatment include 
ulcerations and irritation of the mucosal membrane caused by the dye, with frequent 
ingestion potentially resulting in an inflamed oesophagus, larynx and trachea 
(Rossiter, 2014).  
The knowledge of the patient’s lifestyle may be beneficial in preventing future OPC 
infections as lifestyle choices can be changed, and special precautions taken by the 
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patient. Table 2.2 summarises the treatment options of OPC that are currently 
available for patients. 
Table 2. 2: Treatment options for the successful eradication of oropharyngeal 
candidiasis 
Drug Name and 
Class 
Dosage Form Dose and directions for 
use 
Side effects 
Nystatin  
(Local antifungal) 
Suspension 100 000 IU/ml  
Instil 1 ml – 2 ml of 
suspension into the mouth 
every four hours  
Nausea, vomiting, 
mouth irritation, 
diarrhoea.  
Miconazole 
(Local Antifungal) 
Gel  50 mg – 100 mg  
Apply 50 mg – 100 mg 
three to four times a day  
Nausea, vomiting, 
burning sensation at 
applied area, 
diarrhoea. 
Fluconazole 
(Systemic Antifungal- 
for severe cases) 
Tablets  200 mg/ day  
Take 200 mg daily for 14 
days 
Nausea, vomiting, 
skin rash, abdominal 
pain. 
Chlorhexidine 
(Disinfectant, Broad 
spectrum antiseptic) 
Solution  15 ml – 30 ml to gargle and 
spit out every four hours  
Discoloration of 
tongue and surface 
enamel.  
Gentian Violet 
(Antiseptic dye, 
Antifungal) 
Solution  Use the brush provided to 
paint the affected area at 
least three times a day. 
Mouth 
discolouration, 
ulceration and 
irritation of the 
mucosa, inflamed 
larynx and trachea.  
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2.2 Nystatin 
2.2.1 Introduction. 
Fungi such as the Candida species are known to be the causative organisms of 
numerous opportunistic infections. If these opportunistic infections are not treated 
correctly, they may lead to a decrease in the quality of life of the patient or in extreme 
cases, a systemic infection, thereby causing death (Mazu, Bricker, Flores-Rozas, & 
Ablordeppey, 2016). Opportunistic fungal infections such as OPC may be treated with 
antifungal agents. Antifungal agents are a pharmacological class of antimicrobials that 
may be used to successfully treat fungal diseases, including both opportunistic and 
primary fungal infections. As per the NDoH’s essential drugs list of South Africa, the 
first line treatment of OPC in South Africa is nystatin (South African Department of 
Health, 2012). Although there are many antifungal agents that may be used to treat 
OPC, nystatin is the preferred drug. This is because Candida species do not develop 
resistance against it and it can be applied topically to the affected area and does not 
have any drug interactions (Rossiter, 2014). Nystatin has unique characteristics and 
exhibits a concentration dependent fungicidal activity and a post-fungal effect. 
Concentration dependence means that the higher the concentration that enters the 
cells for elimination, the better. The post-fungal effect means that even after nystatin 
has been removed from the affected area, it is known to still have antifungal activity 
(Gunderson, Hoffman, Ernst, Pfaller, & Klepser, 2000). This made nystatin the drug of 
choice for this study. 
2.2.2 Pharmacological actions. 
Nystatin is an antimycotic polyene antibiotic, obtained during various fermentation 
processes using Streptomyces noursei. Nystatin is indicated for the treatment of 
cutaneous or mucocutaneous mycotic infections caused by Candida species 
(Rossiter, 2014). It has been found to have both fungistatic and fungicidal properties 
against a wide variety of yeasts-like fungi and other organisms such as Candida 
parapsilosis, Candida tropicalis, Candida guilliermondi and Candida krusei. However, 
nystatin does not show any activity against protozoa, viruses or bacteria. Due to the 
intestine’s inability to absorb nystatin, it is a good antifungal agent for the treatment of 
fungal infections affecting the gastro intestinal tract (Brescansin et al., 2013).  
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Coutinho and colleagues (2004), as well as Katzung and colleagues (2012) have 
found nystatin to cause cell death by binding to sterols found on the cell membrane of 
susceptible species, resulting in the leakage of intracellular components due to 
increased permeability of the cell membrane. Lyu and colleagues (2016) recommend 
that 1-2 mL of nystatin suspension containing a dose of 100 000 IU per mL should be 
instilled in the mouth four times a day, for a duration of 1-2 weeks, for successful 
treatment of non-severe OPC (Rossiter, 2014). For nystatin to work effectively, it 
needs to be in constant contact with the affected area of the mouth for as long as 
possible. However, nystatin does not adhere well to the affected area of the mouth as 
the nystatin suspension does not have good adhesion properties. This allows it to be 
washed away by saliva during normal processes such as eating and drinking. 
Therefore, patients should be counselled on taking nystatin after they have eaten or 
have something to drink. The side effects associated with nystatin use include nausea, 
vomiting, mouth irritation and diarrhoea (Rossiter, 2014).  
2.2.3 Physical properties of nystatin. 
Nystatin is available as a yellow to brown powder with a distinctive odour and an 
unpleasant taste. The powder is both hygroscopic and highly lipophilic with a log P 
value of 7.08 and a chemical formula of C47H75NO17. It has a molecular weight of 
926.107 g/mol. It should be stored in an air-tight container in a dark and cool place 
away from direct sunlight. Nystatin is not soluble in water or alcohol; however, it is 
completely soluble in dimethyl sulphoxide and dimethylformamide and is slightly 
soluble in methanol. This is due to its chemical structure, illustrated in Figure 2.3, which 
contains a large lactone ring with numerous double bonds, which makes nystatin both 
amphoteric and amphiphilic. This means that nystatin is almost insoluble in aqueous 
media, which causes solubility challenges when formulating (Campos et al., 2012). 
Because of its low solubility in aqueous media, nystatin tends to have a low 
bioavailability (Gajdošová et al., 2016). Incorporating nystatin into a micellar system 
incorporated into a mucoadhesive film which may allows for increased stability of the 
drug and it also promotes the drug to be released at a controlled rate at the site of 
infection. These properties greatly improve nystatin’s bioavailability and decreases the 
dose frequency thus combating the issue of high treatment failure and recurrence of 
oral thrush (Gelperina, Kisich, Iseman, & Heifets, 2005). 
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Figure 2. 3: Chemical structure of nystatin (Brescansin, Brescansin, Portilho, & 
Pessine, 2013).  
In Figure 2.3 the pink shaded area represents the large lactone ring, the blue arrow 
represents the lipophilic area of nystatin as characterised by the numerous double 
bonds that are present. The green arrow represents the more hydrophilic portion of 
nystatin, this is characterised by the single bonds and the presence of the hydroxyl 
(OH) functional group. 
2.3 Nanotechnology/ Nanoscience 
2.3.1 Introduction.  
The most challenging part in drug formulation is finding a drug delivery system which 
will ensure that the drug is delivered to the part of the body where it is needed without 
affecting other healthy organs (De Jong & Borm, 2008). A new kind of science which 
makes delivering drugs to the diseased area easier is nanoscience. Nanoscience has 
gained significant attention in recent years due to its potential to revolutionise 
numerous aspects of life such as medicine, chemistry and physics (Park, 2007). 
According to the National Nanotechnology Initiative (2017), a nanoparticle is defined 
as a structure with at least one of its dimensions being within the size range of 1 to 
100 nm (Safari & Zarnegar, 2014). However, in the context of drug delivery, a 
nanoparticle can be defined as a structure within the size range of 10 nm to 1000 nm 
(Jong & Borm, 2008). This is because the nanoparticle may be larger in size than the 
stipulated dimensions, as it may have drugs incorporated into its matrix or on the 
surface of the particle (Suri, Fenniri, & Singh, 2007).  
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The unique size of nanoparticles provides them with new properties that the normal 
bulk product would not have, thereby making nanoparticles ideal for drug delivery. 
Some of these unique properties include: their large surface to mass ratio, which 
allows highly insoluble drugs like nystatin to become more soluble (Jong & Borm, 
2008), thereby enhancing the bioavailability of the drug (Mudshinge, Deore, Patil, & 
Bhalgat, 2011); its small size which allows it to have a longer residence time in the 
body, thus increasing the half-life of the drug (Alton & Taylor, 2013); and the size of 
the nanoparticles which allows them to accumulate, using the enhanced permeation 
and retention effect (Nehoff, Parayath, Domanovitch, Taurin, & Greish, 2014) or active 
targeting (Mudshinge et al., 2011), in inflamed and/or diseased tissue, therefore 
increasing the efficacy of the drug. Since the drug goes directly to the affected area, 
lower doses and concentrations of the drug are needed to initiate a therapeutic effect, 
which decreases the chances of a dose-related toxicity (Mudshinge et al., 2011).  
Nanoparticles for use in the body may be composed of biodegradable materials such 
as solid lipids, polymers (natural or synthetic), and metals (Suri et al., 2007). Once the 
nanoparticle containing the drug reaches its site of action, the drug will be released 
either through degradation, erosion or diffusion (Barakat, Taleb, & Salehi, 2011). For 
the context of this study, only nanoparticles which may be used to encapsulate drugs 
such as liposomes, solid lipid nanoparticles (SLN) and polymeric micelles 
(Wilczewska, Niemirowicz, Markiewicz, & Car, 2012) will be discussed. Polymeric 
micelles are the nanoparticle of choice due to its suitability for drugs that are poorly 
soluble in water, such as nystatin (Gaucher, Satturwar, Jones, Furtos, & Leroux, 2010; 
Taillefer, Jones, Brasseur, van Lier, & Leroux, 2000). 
2.3.2 Nanoparticles for drug delivery. 
Liposomes are small artificial vesicular sacs composed of one or more phospholipid 
bilayers surrounding an inner aqueous space. They are synthesized using natural non-
toxic phospholipids and cholesterol. Liposomes are ideal for drug delivery systems 
due to their large size (80-300 nm) and hydrophobic and hydrophilic character 
(Akbarzadeh et al., 2013). Solid lipid nanoparticles (SLN) are nanoparticles that are 
composed of solid lipids such as complex glyceride mixtures, highly purified 
triglycerides or waxes stabilized by various surfactants. Some characteristics 
associated with SNL include their ability to protect the drugs that have been 
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incorporated into them from degradation. This is due to their good physical stability 
(Wilczewska et al., 2012). However, the nanoparticle of choice for this research is the 
polymeric micelle as they have several advantages over the other nanoparticles 
available for drug delivery. Some of these advantages include their smaller size as 
compared to other nanoparticulate drug carriers, which allows them to evade the 
mononuclear phagocyte system (Taillefer et al., 2000).  
2.3.3  Polymeric micelles. 
Micelles are small amphiphilic spherical structures which contain a hydrophilic shell 
and a hydrophobic core with a size range of about 5-100 nm. Micelles are composed 
of amphiphiles or surface-active agents known as surfactants (Oerlemans et al., 
2010). Surfactant micelles had been the popular choice of micelles for many years but 
due to their high critical micelle concentration (CMC) which causes instability, they are 
no longer popular. Polymeric micelles, however, have a low CMC, which renders them 
more stable and tolerable. The low CMC allows polymeric micelles to have a higher 
drug carrying capacity and a better control release profile (Ahmad et al., 2014). 
Polymeric micelles have recently gained attention due to their ability to carry drugs 
that are poorly soluble in water and their enhanced stability as compared to surfactant 
micelles. Polymeric micelles are composed of block copolymers (Kedar, Phutane, 
Shidhaye, & Kadam, 2010). A block copolymer is a polymer which consists of two 
monomers that cluster together to form repeating units (Helmenstine, 2016) as shown 
in Figure 2.4. A polymeric micelle’s hydrophobic core contains the hydrophobic portion 
of the block copolymer. The core is where drugs which are poorly soluble in an 
aqueous media are encapsulated. The outer shell of the polymeric micelles is 
composed of the hydrophilic portion of the block copolymer which protects the 
encapsulated drug from the surrounding aqueous environment and also aids in 
stabilizing the micelle (Kedar et al., 2010) as shown in Figure 2.5. For the micelles to 
be able to encapsulate a drug, the block copolymers that make up the hydrophobic 
core must be compatible with the drug to be encapsulated (Lu & Park, 2013). Polymers 
which offer good sustained release are characterised by being physically interactive 
with the encapsulated drug, thus causing drug retention and a slow release of the drug 
(Trivedi & Kompella, 2010). The polymers must have a low toxicity and they must be 
biocompatible. 
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Figure 2. 4: An illustrative drawing of a linear styrenic tri-block copolymer 
(Eastman Chemical Company, 2017). 
2.3.4 Formation of polymeric micelles. 
According to Jones and Leroux (1999), two forces drive the spontaneous formation of 
micelles: attractive and repulsive forces. During self-assembly of polymeric micelles 
(Xu, Ling, & Zhang, 2013) attractive forces cause the association of molecules while 
the repulsive forces prevent the uncontrolled growth of the micelles such that they are 
no longer in the nano range (Jones & Leroux, 1999). Polymeric micelles form 
spontaneously when amphiphilic block copolymers are exposed to an aqueous 
solution (Xu et al., 2013), as shown in Figure 2.5. For micelles to spontaneously form 
in an aqueous medium, the concentration of the block copolymers must increase 
above a concentration threshold known as the CMC (Jones & Leroux, 1999; Xu et al., 
2013). Formation of micelles above the CMC is due to the dehydration of the 
hydrophobic tails, consequently causing a favourable state of entropy (Oerlemans et 
al., 2010). Once the CMC has been reached, the hydrophobic portions of the block 
copolymer come together so as to avoid contact with the aqueous environment and 
the more hydrophilic portion of the block copolymer will come into contact with the 
aqueous environment. This association of the hydrophobic portions leads to the 
formation of a micellar core (Jones & Leroux, 1999). 
  
 
18
 
Figure 2. 5: The formation of a drug loaded polymeric micelle in an aqueous 
solution (Jhaveri & Torchilin, 2014) 
2.4 Mucoadhesion  
2.4.1 Introduction.  
Bioadhesion has been described by several authors as the attachment of two 
surfaces, held together by interfacial forces for a certain period, with at least one of 
the materials being biological (Amit, Sharad, & Junaid, 2011; Donnelly et al., 2011; 
Mansuri, Kesharwani, Jain, Tekade, & Jain, 2016). Mucoadhesion is a type of 
bioadhesion in which the biological surface is a mucous membrane (Amit et al., 2011). 
Mucoadhesion, as a drug delivery method, has gained interest in the pharmaceutical 
industry since the early 1980’s. This is because mucoadhesive systems enable 
intimate contact of the dosage form with the surface of the diseased organ. This 
increases the retention time of the drug, leading to increased therapeutic efficacy 
(Mansuri et al., 2016). The use of mucoadhesive systems for drug delivery is 
recommended for drug molecules that undergo extensive first-pass metabolism, are 
degraded in an acidic medium and molecules with a high-molecular-weight, such as 
peptides and oligonucleotides (Donnelly et al., 2011). Mucoadhesive drug delivery 
systems may be formulated to deliver drugs via the ocular, oral, buccal, sublingual, 
nasal, enteral, rectal and vaginal routes, for both local and systemic effects (Mahajan, 
Kaur, Aggarwal, & Harikumar, 2012).  
The desired characteristics associated with mucoadhesive systems for drug delivery 
include their size, taste, release rate of drug from the mucoadhesive system, texture 
of the mucoadhesive system and ease of use. The size of the mucoadhesive film 
should be small and flexible to increase patient acceptance. The film must be able to 
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release the drug at a controlled rate; it should be tasteless and not cause any irritation 
to the area of the mucosa where it was placed. Appearance-wise, the film must have 
a smooth surface (Boddupalli, Mohammed, Nath, & Banji, 2010). Some of the 
advantages associated with the use of mucoadhesive films are: their ability to increase 
residence time of the drug at the diseased area, which increases the absorption of the 
drug at the required site, therefore increasing the therapeutic efficacy of the drug. The 
films are also easy to apply, and treatment may be terminated by simply removing the 
film (Phanindra, Moorthy, & Muthukumaran, 2013). The drug within the film is released 
at a slow rate, thereby improving patient compliance, as the patient does not have to 
apply the film multiple times a day (Kaur & Kaur, 2012). For the proposed drug delivery 
method to overcome the shortcomings experienced with the nystatin suspension, the 
drug encapsulated micelles need to be incorporated into a mucoadhesive film, for the 
oral route of delivery, to provide a local effect in the mouth. 
2.4.2 Mucous membrane. 
According to Darling and Daley (2005), a mucous membrane is the moist lining that 
lines the cavities and canals of the body that lead to the external environment such as 
the eyelids, mouth and nose. The mucous membrane is composed of a mucus layer 
which accounts for the moist surface of the membrane. Below it is the epithelial layer 
and below the epithelial layer is the lamina propia, which is made up of connective 
tissue. Depending on the area where the mucous membrane is found, the epithelial 
layer may be composed of single or multiple layers. A single layer of epithelial tissue 
is found in the bronchi, the stomach, small and large intestines. Multi-layered epithelial 
tissue is found in mucous membranes that line the cornea, oesophagus, mouth and 
vagina. In the mouth, mucus is secreted onto the epithelial tissue by the salivary glands 
(Boddupalli et al., 2010). 
Mucus is composed of inorganic salts, water, lysozyme, immunoglobulins, defensins, 
growth factors, trefoil, lipids and mucin (high-molecular-weight-glycoproteins). Water 
accounts for 95% of the weight of mucus, causing it to be extremely hydrated 
(Williams, Sharafkhaneh, Kim, Dickey, & Evans, 2006). Mucin gives mucus the elastic 
and viscous gel-like property that it is known for (Bansil & Turner, 2006). The function 
of mucus is to act as a physical and chemical barrier to pathogens, to lubricate and 
hydrate the epithelial tissue and to allow for the permeation of nutrients and gasses 
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(Derrien et al., 2010). Mucin, which is the largest component of mucus besides water, 
is composed of heavily O-glycosylated molecules which are produced by specialised 
mucus cells. Mucoadhesion is possible due to the mucin glycoproteins showing 
hydrophobic, electrostatic and hydrogen bonding interactions which facilitate 
mucoadhesion (Bansil & Turner, 2016). 
2.4.3 Mechanism of mucoadhesion. 
The mechanism by which mucoadhesion occurs is divided into two stages, as 
illustrated in Figure 2.6, namely: the contact stage and the consolidation stage. During 
the contact stage, contact occurs between the mucous membrane and the 
mucoadhesive (Kaur, 2012). This intimate contact allows the mucoadhesive to spread 
and swell over the mucous membrane, resulting in increased surface contact. An 
increase in surface contact initiates the process of a deep contact of the mucoadhesive 
with the mucous layer, of the mucous membrane (Boddupalli et al., 2010; Phanindra 
et al., 2013).  
At the contact stage, both attractive and repulsive forces are present. However, for 
mucoadhesion to take place, the attractive force must be stronger than the repulsive 
force (Phanindra et al., 2013). In the consolidation stage, moisture is needed to 
activate and plasticize the mucoadhesive. Moisture allows the molecules and polymer 
chains within the mucoadhesive to break and link up using weak van der Waals and 
hydrogen bonds within the mucus (Boddupalli et al., 2010). The consolidation stage 
may be explained using both the diffusion theory and the dehydration theory.  
  
 
21
 
Figure 2. 6: An illustration of the mucoadhesion theory (Jain, Gulati, Kumar, & 
Nagaich, 2012) 
2.4.4 Theories of mucoadhesion.  
Mucoadhesion is a complex process that is not well understood. Numerous theories, 
which explain the mucoadhesive process, have been identified in a bid to help with the 
understanding of the experimental observations of mucoadhesion (Boddupalli et al., 
2010). These theories include: Adsorption theory, diffusion theory, electrostatic theory, 
fracture theory and the wetting theory. The shortcomings associated with the theories 
are that they explain a fraction of the interactions that occur during the mucoadhesive 
bonding (Carvalho, Bruschi, Evangelista, & Gremião, 2010).  
2.4.4.1 Adsorption theory.  
This theory posits that for mucoadhesion to take place, several surface interactions, 
namely primary and secondary bonding between the mucous substrate and the 
adhesive polymer, need to occur after the initial contact of the two surfaces (Boddupalli 
et al., 2010). These surface interactions are due to interactions of the chemical 
structures found on the surface of the polymer and the mucus substrate (Donnelly et 
al., 2011). Primary bonds occur because of chemisorption and lead to strong 
undesirable bonds such covalent, metallic and ionic bonds. These bonds are 
undesirable because they are permanent and thus would not allow the patient to easily 
remove the mucoadhesive film without injuring themselves. The most desirable and 
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prominent bonds in adsorption theory are the secondary bonds (Amit et al., 2011). 
These bonds are desirable because they require less energy to break which allows 
the mucoadhesive film to be removed easily without causing injury. Examples of 
secondary bonds are van der Waal’s forces, hydrogen bonding, and hydrophobic 
bonding (Donnelly et al., 2011). 
2.4.4.2 Diffusion theory. 
The diffusion theory proposes that the glycoproteins found in the mucous interact 
through the interpenetration of the polymeric chains from the mucoadhesive, into the 
glycoprotein mucin chains. When the interpenetration reaches a sufficient depth within 
the other matrices, it forms secondary bonds which are semi-permanent. The deeper 
the interpenetration of mucin and polymer chains, the greater the force of adhesion 
(Boddupalli et al., 2010). The rate of penetration is dependent on the diffusion 
coefficient, the nature of the mucoadhesive chains, contact time, flexibility and 
mobility. For this interaction to occur, the mucoadhesive system must have 
characteristics that allow for both mechanical interactions and chemical interactions; 
such as the mucus having a similar chemical structure to the mucoadhesive polymer. 
The more similar the structures are, the stronger the mucoadhesive bonds. According 
to Donnelly and colleagues (2011), the necessary depth, for good mucoadhesion to 
occur, is estimated to be in the range of 0.2–0.5 μm (Donnelly et al., 2011; Amit et al., 
2011). The depth of interpenetration (I) may be determined using the equation:  
Equation 2.1: determination of depth of interpenetration 
l = (tDb)½ 
Equation 2.1: Where t is the contact time and Db is the diffusion coefficient of the 
mucoadhesive material in the mucus (Boddupalli et al., 2010) 
2.4.4.3 Electrostatic theory.  
The electrostatic theory of mucoadhesion postulates that the mucoadhesive material 
and the mucus membrane both have opposing electrical charges. When the two 
materials come into contact with each other, this results in electron transfer, which 
ends up building a double electronic layer at the surface interface. The strength of 
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the attractive forces in the layer is equal to the strength of the adhesion (Amit et al., 
2011; Carvalho et al., 2010; Donnelly et al., 2011).  
2.4.4.4 Fracture theory. 
The fracture theory of mucoadhesion states that the mechanical strength needed to 
separate the mucoadhesive material from the surface on which it is attached is 
equivalent to the adhesion strength. This statement is represented in the following 
equation: 
Equation 2.2: mathematical equation behind the fracture theory 
σ = (E × ε/L)1/2 (7) 
Equation 2.2: where σ is the fracture strength, ε fracture energy, E is the young 
modulus of elasticity, and L is the the critical crack length (Boddupalli et al., 2010; 
Donnelly et al., 2011). 
2.4.4.5 Wetting theory. 
The wetting theory is the oldest theory of mucoadhesion. It suggests that the 
mucoadhesive agent can spread over and penetrate the irregularities found in the 
mucus membrane, resulting in the adhesive material hardening and creating many 
adhesive anchors. In order to move freely at the surface, the mucoadhesive material 
must have the ability to overcome the surface tension. This theory has been shown to 
apply to low viscosity adhesives and liquid adhesives. The degree of adhesion is 
measured by the contact angle of the mucoadhesive material over the mucoadhesive 
surface; the smaller the contact angle the greater the affinity for adhesion (Amit et al., 
2011; Carvalho et al., 2010; Mansuri et al., 2016). 
2.4.5 Mucoadhesive polymers. 
Mucoadhesive materials are usually polymers that consist of hydrophilic groups such 
as carboxyls amides, hydroxyls and sulphates. The hydrophilic groups attach 
themselves to the mucus membrane using interfacial forces. The ideal polymer for 
mucoadhesion must have the following characteristics: the materials and the by-
products must be non-toxic and non-absorbable by the human body; the polymer 
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should not irritate the area that it comes into contact with and it should form a strong 
noncovalent bond with the mucus membrane. A strong non-covalent bond is ideal as 
it is strong enough to attach the mucoadhesive in place for as long as is needed but 
weak enough to be taken out without ripping the mucus membrane. The material 
should easily allow a drug to be incorporated into it and not hinder the drug’s release. 
It should also adhere quickly to the moistened area it encounters. The polymer must 
be stable enough not to decompose while it is being stored and it must be affordable 
(Donnelly et al., 2011). 
The polymers used in mucoadhesion can be divided into three categories:  
1. Polymers that adhere through nonspecific, noncovalent interactions which are 
mostly electrostatic in nature.  
2. Polymers that have hydrophilic functional groups that form hydrogen bonds with 
other similar functional groups on the mucus membrane.  
3. Polymers that bind only to receptor sites on cells or the mucus surface; this 
category includes thiolated polymers and lectins (Donnelly et al., 2011). 
 Factors such as hydrophilicity, cross-linking, swelling, molecular weight, pH and the 
concentration of the active polymer affect mucoadhesion. 
2.4.6 Polymer factors affecting mucoadhesion. 
Mucoadhesion could be affected by numerous factors such as: molecular weight, 
concentration of active polymer, flexibility of polymer chains, cross-linking density and 
swelling, pH and charge. These are discussed below. 
2.4.6.1 Molecular weight. 
Polymers with a low-molecular-weight are ideal for interpenetration and polymers that 
have a high-molecular weight are better suited for entanglements (Donnelly et al., 
2011). According to Amit and colleagues (2011), polymers that have a lower molecular 
weight have an enhanced ability to penetrate the mucus layer, whereas polymers that 
have a high-molecular-weight struggle to get moist quickly, leading the free groups 
that are available for interactions not being exposed. This results in the mucoadhesive 
becoming a loose gel with a high potential of dissolving quickly. 
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2.4.6.2 Concentration of active polymer. 
There is an ideal concentration of polymers to produce the best mucoadhesion. When 
this concentration has been exceeded, the mucoadhesive strength declines 
significantly. This is because the coiled molecules become desolvated thus limiting 
chains that are available for interpenetration (Donnelly et al., 2011). 
2.4.6.3 Flexibility of polymer chains. 
Amit and colleagues (2011) argue that chain flexibility is important for entanglement 
and interpenetration. If the mobility of a chain decreases, the number of polymer 
chains that can penetrate the mucous layer also decrease, resulting in reduced 
mucoadhesive strength (Saraswathi, Balaji, & Umashankar, 2013). 
2.4.6.4 Cross linking density and swelling. 
According to Donnelly and colleagues (2011), cross-linking density is inversely 
proportional to the degree of swelling. If the cross-linking density is low, there will be 
a higher degree of hydration and flexibility. This results in a large surface area and 
therefore better mucoadhesion. A polymer with a low cross-linking density is therefore 
ideal for good swelling (Saraswathi et al., 2013). 
2.4.6.5 pH and charge.  
The pH found at the interfacial surface of the mucoadhesive and the mucus membrane 
can affect the adhesion of mucoadhesive polymers with ionisable groups such as 
those with carboxylic acid end groups. The best adhesion for the polymers is seen at 
a pH range between 4 and 5, with the strength decreasing as the pH increases above 
6. If the local pH is lower than the pka, then the polymer will be unionised, which is 
favourable for mucoadhesion. For good mucoadhesion, mucin reacts better with 
polymers that are undissociated and anionic than cationic polymers. This is because 
the anionic polymers freely form hydrogen bonds with mucin (Amit et al., 2011; 
Donnelly et al., 2011). 
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2.5 Conclusion 
OPC is prevalent in South Africa due to a number of factors such as an increased 
number of patients suffering from HIV/AIDS, and an increase in the life expectancy of 
the South African population. According to Statistics South Africa (2015), in 2015, 
approximately 6.19 million people in South Africa were living with HIV, which had 
increased by 2.7% from 2014. Life expectancy of a citizen in South Africa was 
expected to be 72 years for females and 65 years for males in 2015. According to 
Garcia-Cuesta and colleagues (2014), an increased life span and the poor health of 
patients contribute greatly to OPC prevalence in developed and developing countries. 
OPC may be treated using a number of antifungal agents. 
In South Africa, nystatin suspension is the first line treatment for OPC infections. 
Nystatin is superior to other antifungal agents because there is a lack of resistance by 
the Candida species to nystatin, and there is a low chance of the patient experiencing 
side effects and drug interactions as it is not absorbed in the gut (Campos et al., 2012). 
Because of these advantages, nystatin has become the treatment of choice for OPC 
and for this study. Unfortunately, the current nystatin suspension poses some 
challenges to OPC treatment, as efficacy is hindered by nystatin being easily washed 
away by saliva; this is because the suspension does not have good adherence to the 
affected area. To improve the problem of retention time and prevent recurrence of 
OPC, loading a polymeric micelle with nystatin and incorporating that into a 
mucoadhesive film may ensure that nystatin is in constant contact with the affected 
area. The mucoadhesive system may also ensure that the drug is released in a more 
controlled manner (Gajdošová et al., 2016).  
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CHAPTER 3 
Methodology 
3.1 Pre-Formulation 
3.1.1 Solubilisation of nystatin. 
3.1.1.1 Introduction. 
It is important for a drug that is intended for clinical use to be water soluble as solubility 
is directly linked to absorption (Benet, 2013). The Biopharmaceutics Classification 
System (BCS) is a scientific system that is used to differentiate drugs according to 
their permeability and solubility as shown in Figure 3.1 (Arrunátegui, Silva-Barcellos, 
Bellavinha, Ev, & Souza, 2015; Benet, 2013; Ku, 2008). The BCS system divides 
drugs into four classes; class I, class II, class III and class IV. Drugs that are highly 
soluble and permeable are placed in class I; drugs with a low solubility and high 
permeability belong to class II; whereas drugs that have a high solubility and low 
permeability belong to class III; and drugs with a low solubility and low permeability 
belong to class IV (Arrunátegui et al., 2015; Benet, 2013; Ku, 2008). 
It is advantageous for a drug to have a high solubility as this means that it can be 
easily solubilised, thus, solubilisation will not hinder the rate of absorption of the drug. 
Drugs with high permeability are also advantageous as this ensures that the drug can 
be fully absorbed (Benet, 2013). Nystatin belongs to class IV due to its low solubility 
and low permeability properties. It is difficult to make formulations using drugs 
belonging to class IV, because absorption of the drug is a problem (Ghadi & Dand, 
2017). In order to improve nystatin absorption in the oral cavity, it is important to find 
a solvent that can solubilise nystatin. To achieve this, a statistical model was used to 
show the optimal nystatin solubilisation using dimethylformamide (DMF), methanol 
and reverse osmosis water. 
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3.1.1.2 Statistical approach to Nystatin solubilisation. 
Nystatin solubilisation was tackled statistically using a mixture design, utilising the 
statistical software Design-Expert version 7.00 (Stat-Ease Inc). A mixture design is a 
special form of response surface methodology (RSM). This type of design assesses 
the end product of a mixture based on the different proportions of the solvents added 
and not based on the amount of the mixture. RSM is a sequential procedure that 
combines both statistical and numerical techniques to develop, improve and optimize 
products and processes (Karimi, Abdollahi, Aslan, Noaparast, & Shafaei, 2010; 
McCarron, Woolfson, & Keating, 1999; Mourabet, El Rhilassi, El Boujaady, Bennani-
Ziatni, & Taitai, 2017). The responses obtained in a mixture design are a function of 
the proportions of the different mixtures that were used. This means that the quality of 
nystatin solubility will depend on the relative proportion of the different components 
being investigated.  
Class I 
High Solubility, High Permeability  
Class II 
Low Solubility, High Permeability  
Class III 
High Solubility, Low Permeability  
Class IV 
High Solubility, Low Permeability  
Figure 3. 1: A diagram showing the different BCS classes and what drug properties 
belong in each class (Milne et al., 2012) 
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The experimental design used was a simplex centroid. This design illustrates that the 
sum of the mixture components is equal to 100% and the experimental space is shown 
as a triangular plot known as the simplex plot (shown in Figure 3.2). Each side of the 
triangle represents an axis (x-axis, y-axis and z-axis), each axis is scaled so that when, 
for example, the x-and y-axis are equal to zero the z-axis will be equal to 100% as 
shown in Figure 3.2 (Karaman, Yilmaz, & Kayacier, 2011; Weisstein, 2013). A simplex 
centroid design only shows runs that are the centroid points. This means that for each 
component that appears in a run in a simplex centroid design, the values may be 
repeated. This is illustrated in Figure 3.2, where the experimental components of run 
are shown on the centroid points. As can be observed from point 2 (½, ½, 0), point 4 
(0, ½, ½) and point 6 (½ ,0, ½,), the values of the solvents to be mixed are the same 
but the values are alternated for each solvent. Each of the three points has a 0 value 
and two values that are non-zero. These points are known as second degree 
centroids. Point 0 (1/3, 1/3, 1/3) in Figure 3.3 is known as the third-degree centroids; this 
point shows that all three points have the same value and no 0 values. Point 1 (1,0,0), 
point 3 (0,1,0) and point 5 (0, 0, 1) are known as first degree centroids as they have 
only one non-zero value and two zero values. The three solvents being investigated 
were DMF, methanol and reverse osmosis water, all with a low value of 0% and a high 
value of 100%. For a design with 3 solvent components, the highest degree of 
centroids will be 3. The points discussed above are known as the overall centroid. This 
design type allows for a reduced number of experiments for the determination of 
nystatin solubility by using high order polynomial models (Ferreira-Nunes, Gratieri, 
Gelfuso, & Cunha-Filho, 2017). The model was evaluated using Analysis Of Variance 
(ANOVA) and a simplex plot, also known as a ternary diagram. 
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Figure 3. 2: A diagram showing the three axes of a ternary diagram (Akhavan, 
2009). 
  
Figure 3. 3: An illustration of the simplex centroid design (Reliability 
Engineering Resources, 2018) 
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3.1.1.3 Materials and equipment. 
Nystatin, DMF were obtained from Sigma Aldrich, St. Louis, United States of America. 
Methanol was procured from Merck Laboratory Supplies (Pty) Ltd, Midrand, South 
Africa and reverse osmosis water was prepared using a Purite Select HP40 GP water 
purification system (Purite, Thame, United Kingdom) at the Nelson Mandela 
University, Pharmacy department (Port Elizabeth, South Africa). 
3.1.1.4  Procedure. 
The following method was adapted from the International British Pharmacopeia (World 
Health Organisation, 2014). A fixed amount of nystatin powder (22.73 mg) was 
solubilised using a varied amount of methanol, DMF and distilled water (World Health 
Organisation, 2014) in a single beaker as shown in Table 3.1. This was done so that 
the ratios between the three solutions at which nystatin could be solubilised in could 
be identified. A hundred percent of the solution was 55 ml. In combinations where 
DMF is present, DMF was added first and a stirring rod was used to solubilise the 
nystatin in the DMF before other solvents were added. In solutions where only water 
and methanol were used or only methanol or only water was used, a magnetic stirring 
rod was placed in the beaker and left to stir for a maximum of 30 minutes at room 
temperature, then the mixture was assessed to see if all the nystatin had solubilised. 
The quality of solubilisation was then graded on a scale of 1 to 3; with 3 being well 
solubilised and 1 meaning that nystatin was not solubilized at all. Table 3.1 shows that 
some of the experimental runs were replicated. This was to ensure that the 
experimental design was reproducible and had adequate precision (Vaux, Fidler, & 
Cumming, 2012).  
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Table 3. 1: The different ratios at which the solvents were used for the 
solubilisation of nystatin 
Run Methanol (%) DMF (%) Water (%) 
1 0 100 0 
2 16.667 66.667 16.667 
3 50.00 0.00 50.00 
4 50.00 50.00 0.00 
5 0.00 0.00 100.00 
6 100.00 0.00 0.00 
7 0.00 0.00 100.00 
8 50.000 50.00 0.00 
9 100.00 0.00 0.00 
10 66.667 16.667 16.667 
11 0.00 50.00 50.00 
12 16.667 16.667 66.667 
13 0.00 100.00 0.00 
14 33.333 33.333 33.33 
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3.1.2 Analytical method development: High Performance Liquide 
Chromatography (HPLC) method.  
3.1.2.1 Introduction. 
HPLC is a type of liquid chromatography that uses separation technique to analyse 
the quality of drugs, proteins, amino acids, nucleic acids, lipids, carbohydrates, 
vitamins and some biologically active molecules (Coskun, 2016; Siddiqui, AlOthman, 
& Rahman, 2017; Thammana, 2016). It also allows for the quantification and 
identification of active compounds and impurities that are present in an analyte, even 
at low concentrations. Because HPLC is multifaceted, it has become the analytical 
method of choice for many industries such as the environmental, chemical and 
pharmaceutical industry (Thammana, 2016). HPLC works by separating components 
of the analyte, based on the polarity of the analyte and the interaction of the analyte 
with the adsorbent stationary phase. When the analyte interacts with the stationary 
phase, the different components of the analyte are separated based on their polarity. 
This separation affects the retention time of the components of the analyte, thus 
helping with the identification of the different components of the analyte (Coskun, 
2016). 
The HPLC system consists of an autosampler, a column (stationary phase), mobile 
phase reservoir, pumps, detector and an oven, as shown in Figure 3.4. The high-
pressured pumping system generates the specific flow of the mobile phase to the 
stationary phase and then to the detector. The autosampler injects the analyte into the 
stream of the mobile phase, which carries the analyte injected into the stationary 
phase and then to the detector. The stationary phase consists of a column that is 
densely packed with a porous material. The detectors in the system monitor and 
analyse the eluting substance from the column. A reading is then shown on a 
processing unit and a display screen in the form of a chromatogram. Examples of 
detectors include UV spectroscopy, fluorescence, mass spectrometric and 
electrochemical identifiers (Thammana, 2016).  
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Figure 3. 4: A diagram showing the different parts of the HPLC machine (Clark, 
2016)  
 3.1.2.2 Materials and equipment. 
3.1.2.2.1 Materials. 
Nystatin was procured from Sigma Aldrich, St. Louis, United States of America, HPLC 
grade acetonitrile and methanol were obtained from Merck Laboratory Supplies (Pty) 
Ltd, Midrand, South Africa. Ammonium acetate buffer was prepared using ammonium 
acetate salt, glacial acetic acid which were all obtained from  Merck Laboratory 
Supplies (Pty) Ltd, Midrand, South Africa and reverse osmosis water was prepared 
using a Purite Select HP40 GP water purification system (Purite, Thame, United 
Kingdom) at the Nelson Mandela University, Pharmacy department (Port Elizabeth, 
South Africa). 
3.1.2.2.2 Equipment. 
HPLC analysis of nystatin was performed using a Shimadzu LC 20AT System with a 
SPD M20A Photodiode Array (PDA) detector, a DGU 20A5 degasser, an isocratic 
pump and a CTO 20A column oven (Shimadzu, Kyoto, Japan). All injections were 
made through an S/L 20ACHT autosampler with a 100 µL injection loop. A SPD20AV 
wavelength UV/Vis detector was used to monitor the UV absorbance of samples. The 
auto sampler  
HPLC column 
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mobile phase was filtered using a vacuum filter of 0.45 µm pore size, with a Pall GH 
Polypro membrane (GVS life sciences, Bologna, Italy). The pH of the ammonium 
acetate buffer for the mobile phase was tested using a pH meter (Crison, Barcelona, 
Spain). Samples were transferred to 2 ml glass HPLC vials (Thermo Fisher Scientific, 
Waltham, Massachusetts, United States) using 5 ml syringes (Avacare Health, 
Rhodesfield, South Africa) and filtered through 0.45 µm syringe filters (GVS life 
sciences, Bologna, Italy). The stationary phase used was a Supelco C18 column with 
a particle size of 5 μm (Sigma Aldrich, St. Louis, United States of America). 
3.1.2.3  Procedure. 
3.1.2.3.1 Mobile phase preparation. 
A 0.05 M of ammonium acetate buffer at a pH of 6 was prepared by solubilising 
ammonium acetate salts (3.85 g) in reverse osmosis water (1000 ml). Glacial acetic 
acid was added in a dropwise manner to the solution to adjust the pH until the desired 
pH (pH 6) was reached. The final solution was filtered using vacuum filtration through 
a cellulose filter with a pore size of 0.45 μm, before it could be used for HPLC. HPLC 
grade methanol and acetonitrile were used directly from the bottle without filtration. 
The ammonium acetate buffer was not used for longer than 72 hours, because it would 
form precipitates which would affect the HPLC instrument and the analysis of the 
analyte. The mobile phase preparation was based on a method used by Heneedak 
and colleagues (2012).  
3.1.2.3.2 Preparation of stock solution. 
The stock solution was prepared by accurately weighing 20 mg of nystatin and 
solubilising it in 60 ml of methanol; this was considered as 100% concentration. The 
mixture was left under constant stirring for 30 minutes. 10 ml of the solution was 
measured using a measuring cylinder into a beaker. 10 ml of the ammonium acetate 
buffer was measured using a measuring cylinder and added to the beaker containing 
the methanol-nystatin solution to create a 1:1 solution. The solution was then stirred 
for a few seconds and then transferred into a syringe. The solution was then filtered 
through a syringe filter with a pore size of 0.45 µm into an HPLC vial. The vial was 
closed tightly with a vial cap. The stock solution preparation was based on a method 
used by Heneedak and colleagues (2012). 
  
 
36
 
3.1.2.3.3 Chromatographic conditions. 
The mobile phase for the analysis of nystatin consisted of 30% acetonitrile, 40% 0.05 
M ammonium acetate buffer at pH 6 and 30% methanol in an isocratic flow. A C18 
column was used at a temperature of 40 °C. The flow rate of the mobile phase was 
set to 0.8 ml / minute and the wavelength of the detector was set for detection at 250 
nm. The injection volume was set to 5 μl. 
3.1.2.4 Method development. 
3.1.2.4.1 Analytical column of choice. 
A C18 column [-CH2-(CH2)16-CH3] was chosen as the analytical column due to its 
availability in the lab and the wide range of literature available detailing its use in 
quantitative determination of nystatin (Wilson, Stewart, Flournoy, William, & Vancura, 
2001; Heneedak et al., 2012). This resulted in fewer difficulties in finding literature on 
suitable mobile phase conditions for the analytical problem. Therefore, HPLC method 
development was initiated using Supelco C18 column with column dimensions of 150 
mm × 4.60 mm, and a 5 μm pore size. 
3.1.2.4.2 Choice of mobile phase. 
The choice of mobile phase which was a mixture of acetonitrile, ammonium acetate 
buffer and methanol was based on an analytical method developed by Heneedak and 
colleagues (2012). The initial mobile phase consisted of 30% acetonitrile, 10% 
ammonium acetate buffer and 60% methanol. This was adjusted to 30% acetonitrile, 
30% ammonium acetate and 40% methanol. This was adjusted because the initial 
mobile phase had a short retention time of less than 1 minute. The stock solution 
preparation was as per that explained in section 3.1.2.3.2. The initial temperature and 
flow rate described by Heneedak and colleagues (2012) was 45 °C and 1ml / min. This 
was adjusted to 40 °C and 0.8 ml / min, because this also affected the retention time. 
After all the adjustments were made, the retention time improved from less than a 
minute to 3.5 minutes. Initially, the UV detector was set to a wavelength of 230 nm; 
this was adjusted to 250 nm as it yielded the best peak purity. 
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3.1.2.5  Method validation. 
HPLC method validation is a process where the analytical method is investigated for 
accuracy, precision and reliability. The purpose of validation is to ensure that the 
results obtained from the analytical method is reproducible, reliable and suitable for its 
intended purpose (Green, 1996; Paithankar, 2013). 
3.1.2.5.1 Linearity.  
Linearity of an analytical method demonstrates that when analytes are prepared at a 
range of different concentrations, the results show that the area under the curve and 
the peak height is directly proportional to the concentration of the analyte in a linear 
manner (Green, 1996). Linearity of nystatin was tested by preparing samples with a 
concentration range between 200% and 25% (200%, 150% 100%, 75%, 50%, 25%). 
The preparation of the samples is described above in the section on preparation of 
stock solution. All readings were done in triplicates and the area under the curve was 
recorded. The area under the curve was used to plot the calibration curve of the area 
under the curve vs concentration; and a trend line was fitted into the graph. In order 
for an analytical method to be considered linear, the calibration curve needs to have 
a regression line with a correlation coefficient greater than or equal to 0.999 and the y 
value must not be significantly greater than zero. This is true if an assessment value 
(z value) is between 2 and -2 (ICH Harmonised Tripartite Guideline, 2005). The z value 
was calculated using the following equation. 
 
Equation 3.1: equation showing the z value used for the assessment of linearity. 
𝑧 𝑣𝑎𝑙𝑢𝑒 =
y intercept
50% detector response
 × 100 
 
3.1.2.5.2 Accuracy.  
Accuracy of an analytical method is known as the closeness of the measured value to 
the true value of the sample. The true value of the analyte may either be an accepted 
reference value or a conventional true value (Green, 1996; ICH Harmonized Tripartite 
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Guideline Q2A, 2005; Bhadra, Das, Roy, Arefeen, & Rouf, 2011). Accuracy of nystatin 
was determined by preparing samples containing a concentration of 150%, 100% and 
50% nystatin. All readings were done in triplicates with three replicate injections. The 
true values of the analyte, at the various concentrations, was obtained from the linear 
regression line obtained from the linearity tests and they were compared to the values 
obtained for accuracy tests. The Relative Standard Deviations (RSD) of the true values 
were calculated and compared to the RSD values of the samples. This showed if there 
were any variations within the sample. The acceptance criteria were a percentage 
recovery of 100% ± 2%. However, lower ranges between 80% to 120% may also be 
accepted depending on the targeted concentration (Green, 1996). 
3.1.2.5.3 Precision. 
Precision is known as the measure of the closeness of data obtained from multiple 
injections of the same homogeneous analyte, at the same analytical conditions. 
Samples at 100% concentration were prepared using the method mentioned in the 
section on preparation of stock solution. Five vials containing analytes at a 
concentration of 100% were injected in triplicates under the same analytical 
conditions. The mean area under the peaks were calculated along with the RSD. An 
analytical method is deemed precise when the RSD is less than or equal to 2% (Green, 
1996; Bhadra et al., 2011). 
3.1.2.5.4 Specificity. 
Specificity of an analytical method refers to the ability to test an analyte in the presence 
of other components that may be found in the final product. Specificity must detect, 
without a doubt, that the peak obtained is indeed the peak of the desired chemical; 
pure nystatin. Thus, the purity of the peak needs to be checked to ensure that the 
purity angle is less than the threshold angle. The peak purity is determined by the 
photo-diode array detector (PDA), which helps in identifying if there are any impurities 
that are co-eluting with the active ingredient. The PDA detector used in this research 
was the SPD M20A Photodiode Array, which is an advanced type of UV detector. This 
detector is able to give three-dimensional information about the analyte. This 
information allows for an error free assessment of the peak purity, the peak identity 
and the peak quantitation, all in a single run. 
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Specificity was measured by preparing an analyte with a concentration of 100% and 
50 mg of poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PMP) 
which will be present in the final product. The analytes were prepared according to the 
method mentioned in the section on the preparation of stock solution. Three analytes 
were prepared without nystatin and all runs were done in triplicates. For an analytical 
method to be considered specific, it must have a purity index as close to 1 as possible 
with no impurities detected (Green MJ, 1996; Bhadra et al., 2011). For the samples 
without nystatin present there should be no peaks around the time that nystatin elutes. 
3.2  Polymeric Micelle Formulation 
3.2.1 Introduction. 
Polymeric micelles are supramolecular structures that are formed due to self-assembly 
of amphiphilic block polymers. Block polymers are driven to self-assemble as a result 
of electrostatic interactions, hydrophilic and hydrophobic effects, hydrogen bonding 
and metal complexations when the polymers are exposed to water (Mourya, Inamdar, 
Nawale, & Kulthe, 2010). Polymeric micelles have gained attention for drug delivery 
due to their low toxicity, biocompatibility, enhanced blood circulation time and their 
ability to solubilize drugs into the micellar core (Xu et al., 2013). 
3.2.2  Methods and materials. 
3.2.2.1 Materials. 
DMF, poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PMP) and 
nystatin were obtained from Sigma Aldrich, St. Louis, United States of America. 
Reverse osmosis water was prepared using a Purite Select HP40 GP water 
purification system (Purite, Thame, United Kingdom) at the Nelson Mandela 
University, Pharmacy department (Port Elizabeth, South Africa). 
3.2.2.2 Equipment. 
Rotary evaporator with a vertical condenser, R-210 was obtained from Buchi, 
Meierseggstrasse, Switzerland, Snake skin dialysis tubing composed of a 10 K 
molecular weight cut-off of regenerated-cellulose with a diameter of 35 mm to allow 
for the exchange of DMF with water was procured from Sigma Aldrich, St. Louis, 
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United States of America and Zetasizer Nano ZS instrument was procured from 
Malvern Instruments (Pty) Ltd., Worcestershire, United Kingdom. The atomic force 
microscopy (AFM) was obtained from Burke South Africa (Pty) Ltd and transmission 
electron microscopy (TEM) Joel JEM 2100 was obtained from Joel, Tokyo, Japan. A 
Hermle Z300 universal centrifuge which was obtained from Hermle Labortechnik, 
Wehingen, Germany was used for drug entrapment efficiency. 
3.2.3  Statistical method for micelle optimisation.  
The statistical method used for the optimisation of micelle formation was RSM. 
Optimisation using RSM is done by analysing the effects of many independent 
variables on the quality characteristics or the performance measure of the sample 
(Karimi et al., 2010; Mourabet et al., 2017). This method is a convenient technique as 
it allows for fewer experimental runs to show a mathematical trend rather than 
exploring the effects of each variable at a time (McCarron et al., 1999; Bai, Saren, & 
Huo, 2015). RSM aids in investigating the interactive effects of different variables on 
the sample to be created, and also allows for the researcher to measure the 
relationship between the controlled input parameters and the obtained response 
surfaces (Giordano, 2006; Karimi et al., 2010).  
The data obtained from RSM is interpreted using multiple regression analysis to define 
the equation of best fit and using ANOVA to determine how important each factor is 
(McCarron et al., 1999). One of the main requirements for RSM is the need for a design 
of experiments (DoE) in order to achieve reliable and adequate data for the 
measurement of the response of interest (Karimi et al., 2010). DoE is one of the most 
common statistical techniques used for product optimisation. DoE is described as the 
combination of planned experiments that show the relationship of set independent 
variables with independent variables of interest (Oprime, Maria, Pureza, & Conceição 
De Oliveira, 2015). The experimental design methods which are commonly used for 
modelling and process analysis are central composite design (CCD), the full factorial 
and the partial factorial (Karimi et al., 2010). The experimental design used for this 
research was the central composite rotational design (CCRD). CCRD is useful when 
building a quadratic model for the response variables. This design consists of a factor 
which will be varied, with each factor having two levels; usually a high level and a low 
level. The design also has a set of central points, which are the experimental runs with 
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values that do not change; these values are the middle point of the high and low levels 
that had been plotted. These fixed points help to ensure experimental precision. The 
experiment also has a set of experimental runs which are identical to the central point, 
except that one factor is the changed factor which will have values both within the 
lower and higher levels and also outside of these levels (PennState Eberly College of 
Science, 2018).  
3.2.4 Experimental design. 
The two factors that were varied were the temperature of the hydration water added 
to the polymer solution (hydration temperature) and the rotary evaporation time 
(Kulthe, Choudhari, Inamdar, & Mourya, 2012; Saadat, Amini, Khoshayand, 
Dinarvand, & Dorkoosh, 2014). Temperature was chosen as one of the critical factors 
due to micellar formation being temperature dependant (Zhou, Li, Wang, Zhang, & Liu, 
2016). According to Zhou and colleagues (2016), environmental factors such as the 
temperature in which micelle formation takes place can greatly impact the size, shape, 
stability and drug encapsulation efficiency of the micelles formed. Since change in size 
and stability were some of the responses that were being evaluated, the two 
environmental factors which would be investigated were hydration temperature and 
the length of time at which the micellar solution was exposed to the temperature within 
the rotary evaporator. An experiment done by Ai and colleagues (2014), showed that 
hydration temperatures higher than 50 °C resulted in low drug encapsulation efficiency 
and low stability, therefore, the hydration temperatures investigated in this research 
were between 30 °C and 45 °C. There had not been any investigations done on the 
length of time at which the micelles are exposed to the temperature environment of 
the rotary evaporator, so a time of 60 minutes to 180 minutes was investigated. 
This was chosen to aid in evaluating the quantitative relationship between the input 
variables and the response; which are mean particle size, change in mean particle 
size, mean polydispersity index (PDI), change in mean PDI, mean zeta potential and 
change in mean zeta potential. These responses were chosen because they allowed 
for an evaluation of the physical characteristics of the micelles, and the physical 
stability of the micelles. The mean PDI was used as a response as it gave an indication 
of the uniformity of the size of the micelles within the sample solution (Masarudin, 
Cutts, Evison, Phillips, & Pigram, 2015). Variables were inserted into Design-Expert®. 
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A run sheet containing all the different experimental runs was constructed and 
presented in Table 3.2. The central points in this design consisted of a polymeric 
micelle being formed at a condition where the temperature of the hydration water was 
35 °C, and a rotary evaporation time was 135 minutes. The different experimental runs 
were conducted and using Design-Expert software, they were evaluated for change in 
size, PDI and zeta potential. The size, PDI and zeta potential of the micelles were 
evaluated on the day the micelles were formed and 2 weeks after the micelles were 
formed, in order to help establish the stability of the micelles. Table 4 shows some 
duplicate experimental runs; this is to ensure that the experimental run is reproducible 
and that the experimental design has precision (Vaux et al., 2012).  
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Table 3. 2: Experimental runs for micellar formulation, with the different 
variables 
Run number  Temperature (°C) Evaporation Time (min) 
1 35 135 
2 35 135 
3 35 135 
4 35 198.64 
5 35 135 
6 40 90 
7 30 60 
8 27.92 135 
9 35 71.36 
10 35 71.36 
11 40 180 
12 35 135 
13 30 180 
 
3.2.5  Procedure: micelle formation during optimisation. 
For micelle formation, 100 mg of PMP and 10 mg of nystatin were dissolved in 1.5 ml 
of DMF to form a yellow solution. Reverse osmosis water, 10 ml at a temperature of 
30 °C, was added dropwise under stirring to the polymer-DMF-Nystatin solution; this 
makes the solution slightly cloudy indicating the formation of micelles. The solution 
was then transferred into a round bottom flask and placed into a rotary evaporator at 
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60 °C and at a setting 3 on the rotary evaporation equipment. Rotary evaporation 
occurred under a vacuum to aid the removal of DMF from the solution for a varied 
amount of time. Once the micelles were formed in the rotary evaporator, the micelles 
were dialysed, using a dialysis tube which has a diameter of 35 mm, with a 10 K 
molecular weight cut off of regenerated-cellulose to further remove DMF from the 
solution. The required amount of the dialysis tube was cut and soaked in I L of distilled 
water for 15 minutes. Using a rubber band, one end was tied. The micelle solution was 
poured into the tube from the untied end and tied off using a rubber band. The tube 
containing the micelle solution was placed in a 1 L beaker containing 1 L of distilled 
water for four hours. The 1 L water was poured out and replaced with a new batch of 
1 L water every two hours. The micelle preparations were based on a literature written 
by Kulthe and colleagues (2012). 
 3.2.6 Characterisation of micelles. 
Characterisation of micelles is important as the behaviour of the micelles and 
nanoparticles in general depend on their size, surface area and surface reactivity 
(Cong et al., 2011). Depending on how the micelles were formed, their characteristics 
may differ from micelles that were formed using other methods (Kuthle et al., 2012). 
Physical characterisation of nanoparticles enables the researcher to view properties 
such as the size of the nanoparticles, surface morphology, the surface charge of the 
nanoparticles and the percentage drug encapsulation. The chemical characterisation 
of micelles enables the evaluation of the critical micelle concentration (Mourya et al., 
2010).   
3.2.6.1 Size and Zeta potential.  
The size and zeta potential of the micelles were determined using the Malvern ZS 
Nano Zatasizer (Malvern Instruments, Worcestershire, United Kingdom). This is an 
instrument that is widely used for the measurement of size and zeta potential of 
colloids and nanoparticles. It may also be used for the measurement of electrophoretic 
mobility of proteins and microrheology of protein and polymer solutions (Kaszuba, 
Corbett, Watson, & Jones, 2010). The machine was chosen due to its versatility and 
its ability to measure many aspects of the nanoparticles. It also allows for the detection 
of aggregates from small or diluted samples and from samples that are highly 
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concentrated or have a low concentration; thus, a large amount of sample is not 
needed for assessment (Malvern Panalytical, 2017).  
The size of the nanoparticles measured refers to the average particle hydrodynamic 
diameter of the samples. The hydrodynamic diameter of the micelle is known as a 
hypothetical hard sphere that is diffused at the same speed as the particle that is being 
analysed (Malvern Panalytical, 2017). For a polymeric micelle, an average size of 10 
nm to 100 nm is acceptable (Kulthe et al., 2012). To ensure that the size distribution 
of the particles is closely related, the polydispersity index (PDI) is used. The PDI is a 
number that is calculated from a two-parameter fit to the correlation data. The index 
indicates how broad the size distribution of the particles is. If the PDI is greater than 
0.7, this is an indication that the size distribution of the particles is too wide (Kuthle et 
al., 2012).  
Zeta potential is the measure of the repulsive or attractive charge that molecules or 
particles have while in a certain medium. Zeta potential comes from the surface 
charge, the concentration and the types of ions that are present in the solution, and it 
is one of the important methods used to determine the stability of a sample (Kaszuba 
et al., 2010). Zeta potential measurements help with the understanding of causes of 
aggregation, flocculation and dispersion. Samples with a high charge are considered 
more stable and have a less chance of aggregating and flocculating because the 
particles have a stronger repulsion for each other, since they have the same charge 
(Malvern Panalytical, 2017). The stability of a sample may be changed by modifying 
the ionic concertation, pH, and by using surfactants and polyelectrolytes. A zeta 
potential of +30 mv or -30 mv is considered stable.  
The Malvern ZS nano Zetasizer works by using a variety of techniques. For size 
analysis, the dynamic light scattering (DLS) technique and Non-Invasive Backscatter 
optics (NIBS) is used (Malvern Panalytical, 2017). DLS works by measuring the 
diffusion of erratic and random motions of particles that are suspended in a liquid 
(known as Brownian motion), and the intensity and random changes in the intensity of 
the light scattered from the solutes in the suspension. The Malvern ZS nano Zetasizer 
converts the diffusion of the particles into size range by using the Stokes-Einstein 
relationship. The Stokes-Einstein relationship is shown in Equation 4 and 
demonstrates that the rate of diffusion of particles in a suspension at a constant 
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temperature is inversely proportional to the size of the particle (Aschinger et al., 2012; 
Stetefeld, McKenna, & Patel, 2016). Particles that are small tend to diffuse faster than 
particles that are large. The light scatter and the speed of diffusion is measured using 
a sensitive avalanche photodiode detector (APD). The changes in the intensity of the 
light scattered are analysed with a digital autocorrelator which generates a correlation 
function. This results in a curve that shows the size and size distribution of the sample 
(Aschinger et al., 2012; Stetefeld et al., 2016).  
Equation 3.2: The Stokes-Einstein equation 
 
Equation 3.2: The Stokes-Einstein equation showing the relation of size and the 
diffusion coefficient measured by dynamic light scattering. Where Dh is the 
hydrodynamic diameter (this is the goal: particle size), Dt is the translational diffusion 
coefficient (we find this by dynamic light scattering), kB is Boltzmann’s constant (we 
know this), T is thermodynamic temperature (we control this) and η is dynamic 
viscosity 
Particles and molecules were measured for zeta potential by measuring the velocity 
with which they move when they are under the influence of an electric field. When an 
electrical field is applied to particles, particles with a charge tend to move towards the 
electrodes that applies the electrical field (Malvern Panalytical, 2017; Tucker et al., 
2015). The speed at which the particles move is proportional to the electrical field 
strength and their zeta potential. The velocity of the particles is measured using laser 
doppler electrophoresis. This works by applying an electric charge to the solution 
containing the particles or a dispersion of particles. The velocity with which the 
particles move is measured using the Malvern’s patented laser interferometric 
technique called M3-PALS (Phase analysis Light Scattering). The M3-PALS helps to 
calculate the zeta potential by calculating the electrophoretic mobility of the particles 
(Malvern Panalytical, 2017). 
3.2.6.1.1 Sample preparation. 
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The sample of micellar solution was transferred from the dialysis bag into a beaker. 
The micelles were then filtered using a syringe filter with 0.45 µm pore size into a new 
beaker and allowed to settle for a few minutes to eliminate any bubbles that may have 
formed during filtration. The sample of micellar solution was then transferred to a clear, 
disposable, folded capillary DT5106OC (Malvern Instruments, Worcestershire, United 
Kingdom) cell for size analysis, PDI and zeta potential analysis. The scatter angle used 
for the analysis was 173° at a temperature of 25 °C. Water was used as the dispersant 
with a refractive index of 1.330, the temperature was kept constant at 25 °C. All 
samples were analysed three times to minimize error. 
3.2.6.2  Atomic force microscopy. 
Atomic force microscopy (AFM) is a type of high-resolution scanning probe 
microscope. The AFM is a microscope that is designed for three-dimensional 
topography of nanoparticles. It uses a probe to measure properties such as friction, 
height and magnetism of a nanoparticle. AFM was used in this research due to its 
ability to generate three dimensional images of the sample and the great degree of 
accuracy of the microscope (Jagtap & Ambre, 2006; Vahabi, Nazemi Salman, & 
Javanmard, 2013). An AFM system consists of micro-machined cantilever probe which 
has a sharp tip mounted to a piezoelectric (PZT) actuator and a position sensitive 
photo detector (PSPD). The PSPD is used for receiving laser beams that are reflected 
off the top of the cantilever for the detection of cantilever deflection feedback (Vahabi 
et al., 2013), shown in Figure 3.5.  
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Figure 3. 5: The different constituents of a typical AFM system (Mai, 2017) 
The mechanism by which the AFM works is based on the instrument detecting the 
force that the cantilever tip exerts on the surface of the sample. The AFM uses the 
cantilever probe and its sharp tip to scan over the surface of the sample. As the tip 
gets closer to the surface of the sample, attractive forces between the tip and the 
surface of the sample cause the cantilever to bend towards the surface of the sample. 
However, when the cantilever tip gets too close to the sample (when the tip and the 
sample surface touch) repulsive forces are observed between the cantilever tip and 
the surface of the sample; this force causes the cantilever to bend upwards away from 
the surface sample (Jagtap & Ambre, 2006; Vahabi et al., 2013). The PSPD detects 
the bending of the cantilever by detecting the beam that is reflected form the top of the 
cantilever during bending. Bending of the cantilever will cause a slight change in the 
way that the laser beam is reflected; the PSPD tracks the changes. When the AFM is 
scanning an image, it uses the principle explained above. However, a feedback loop 
enables the PZT actuator to control the cantilever tip in a way that it is always at a 
constant height or force away from the surface of the sample. In this way, the AFM is 
able to accurately generate the topography of a sample (Jagtap & Ambre, 2006; 
Vahabi et al., 2013). 
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AFM can be used in three different modes namely the contact mode, the non-contact 
mode and the tapping mode. During contact mode, the sharp tip of the cantilever is in 
constant contact with the sample and the tip is dragged across the surface of the 
sample. When the machine is used in non-contact mode, the cantilever tip does not 
make physical contact with the sample; the tip oscillates about 1 nm to 10 nm away 
from the sample. In tapping mode, the cantilever tip makes contact with the sample 
for a very short time; the tip is not in constant contact but rather it taps the sample 
(Jagtap & Ambre, 2006). 
3.2.6.2.1 Sample preparation. 
One drop of the micelle solution was placed on a mica disk and left to dry at room 
temperature for 48 hours, away from any dust. Once dry, the disk was evaluated using 
AFM (Ruozi, Tosi, Forni, Fresta, & Vandelli, 2005). 
3.2.6.3 Transmission electron microscopy. 
A transmission electron microscope (TEM) is a high-resolution electron microscope 
that generates two dimensional images by using electron beams. The microscope 
shows information such as the morphologic, compositional and crystallographic 
properties of a nanoparticle (Ma, Shieh, & Qiao, 2006). A TEM microscope has the 
following compositions: an electron source, thermionic gun, electron beam, 
electromagnetic lenses, vacuum chamber, two condensers, sample stage, phosphor 
or fluorescent screen and a computer as shown in Figure 3.6. The microscope 
produces high resolution black and white images of the sample. 
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Figure 3. 6: . The constituents of a typical TEM system (Bose, 2017) 
The electron gun generates electrons in the form of an electron beam. A beam is 
emitted that moves through a vacuum present in the microscope. The electron lenses 
ensure that the electrons emitted are focused into a very thin beam that is directed 
through to the sample. When the electron interacts with the sample, some electrons 
are scattered depending on the crystal orientation and the compositional density of the 
sample. The intensity of the un-scattered electrons generates an image which is seen 
on the computer screen (Sunoqrot, Alsadi, Tarawneh, & Hamed, 2017; Ma et al., 
2006).  
3.2.6.3.1 Sample preparation. 
A drop of the micelle solution was applied to a carbon coated copper grid and left to 
dry at room temperature for 48 hours. After the sample was dry, the copper grid was 
placed in the sample holder and imaged using TEM. 
3.3.6.4  Micelle drug encapsulation. 
Drug encapsulation efficiency is known as the ratio of the amount of drug remaining in 
the micelle relative to the amount of drug that was introduced before encapsulation. 
Drug encapsulation of a micelle is influenced by the method of micelle preparation, the 
type of copolymer used and the solubility of the drug (Sunoqrot et al., 2017). A method 
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from Sahu and colleagues (2011), was used to analyse drug encapsulation efficiency 
of the polymeric micelles. Equation 3.3 was used to determine drug encapsulation 
efficiency.  
Equation 3.3: Equation used to determine % drug encapsulation 
𝐷𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛(%)  
= ൬
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑛𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑛𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑝𝑟𝑒𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠
൰ × 100 
 
3.3.6.4.1 Sample preparation. 
The optimal micelles were prepared using the technique mentioned above (3.1.2.3.2). 
The encapsulated nystatin micelles were separated from the un-encapsulated nystatin 
by adding a 1:1 ratio of the micelle to 10 mg/ ml of sodium citrate. The micelle sodium 
citrate mixture was centrifuged for 45 minutes at a rotation of 5000 rotations per minute 
(Li & Chen, 2017). The supernatant was extracted (5 µl) and added to 5 ml of 
ammonium acetate buffer and 5ml of methanol and then filtered through a syringe 
filter. The sample was then transferred to an HPLC vial and analysed using HPLC. 
3.3 Mucoadhesive Film Preparation 
3.3.1 Introduction. 
The use of the oral route for drug delivery remains the best way to deliver drugs. This 
is because orally administered drugs are widely accepted by both authorities and 
patients (Lu & Park, 2013). A Mucoadhesive system was chosen for this study 
because it allows for a more controlled release of nystatin and an increased contact 
time of nystatin with the affected area (Mansuri et al., 2016). Two mucoadhesive 
formulations were used for the formation of the mucoadhesive film. The two films were 
characterised for physical properties such as physical appearance and film pliability. 
The film with the best results from the characterisation was picked as the film of choice 
for the study, and it was further characterised for film weight, film thickness, swelling 
index and drug release studies. 
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3.3.2  Materials and equipment. 
3.3.2.1 Materials. 
Hydroxypropyl methylcellulose (HPMC), Sodium Carboxymethylecellulose (SCMC) 
Polyvinylpyrrolidone K-30 (PVP) and Polyethylene glycol 400 (PEG) were procured 
from Merck Laboratory Supplies (Pty) Ltd, Midrand, South Africa, reverse osmosis 
water was prepared using a Purite Select HP40 GP water purification system (Purite, 
Thame, United Kingdom) at the Nelson Mandela University, Pharmacy department 
(Port Elizabeth, South Africa). 
3.3.2.3 Equipment.   
The equipment and apparatus used for testing the film are as follows: Jenway 3510 
pH meter obtained from Jenway, Staffordshire, United Kingdom. Franz diffusion cell 
procured from Sigma Aldrich St. Louis, United States of America, HPLC equipment 
Shimadzu LC 20AT  obtained from Shimadzu, Kyoto, Japan and a micrometer screw 
gauge procured from Thermo Fisher Scientific, Massachusetts, United States). 
3.3.3  Procedure: preparation of films.  
Mucoadhesive forming polymers were utilized to prepare mucoadhesive films using 
the solvent casting method used by Saxena and colleagues (2011). The HPMC film 
was prepared using 10 ml of reverse osmosis water heated to 90 ⁰C in a glass beaker. 
300 mg of HPMC was weighed and added to the heated water. Once added, the 
polymeric solution was stirred using a magnetic stirrer until the solution became clear. 
6 mg of PVP was weighed and added to the polymeric solution and stirred until the 
mixture became homogenous. The micelles that were previously formed containing 
10 mg of nystatin were added to the mixture, then 0.12 ml of PEG was measured and 
added and stirred until the polymeric solution became homogenous. The polymeric 
solution was then poured into a petri dish and placed in an incubator at 37 ⁰C for 4 
hours.   
The Sodium Carboxymethylecellulose (SCMC) film was prepared using 10 ml of 
reverse osmosis water which was heated to 90 °C using the same method as above. 
400 mg of SCMC was weighed and added to the heated water. The polymer mixture 
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was stirred until it was clear, then 4 mg of PVP was weighed and added to the polymer 
mixture. 0.16 ml of PEG was measured and added to the polymer mixture and stirred 
until the mixture was homogeneous. The nystatin micelles were added to the polymer 
solution as explained in the HPMC method. The polymer solution was then poured 
into a petri dish and placed in an incubator at 37 ⁰C for 4 hours. 
After the films were left to dry, they were characterised. Table 3.3 tabulates the 
different excipients used for each film.  
Table 3. 3: The different excipients used for solvent casting method of the 
mucoadhesive films. 
Excipient  HPMC Film  SCMC Film  
Polymer  (HPMC) 300 mg   (SCMC) 400 mg  
PVP 6 mg 4 mg  
PEG 0.12 ml 0. 16 ml 
Reverse osmosis water 
(at 90 °C) 
10 ml 10 ml 
 
3.3.4 Film characterisation. 
The mucoadhesive film was characterised for physical characteristics such as the 
surface smoothness and physical appearance, folding endurance, surface pH, and the 
swelling index of the film. The film was also characterized for drug release kinetics 
using a Franz diffusion cell (FDC) and tensile strength. 
3.3.4.1 Surface smoothness and physical appearance. 
The surface smoothness test includes observing the films for any visible imperfections 
such as surface texture, clarity, colour and plasticity. It is important for the film to have 
a smooth and uniformed surface and texture as this is preferred by patients. 
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 3.3.4.2 Film weight and thickness. 
Film weight and thickness was explored in order to have a way of assessing whether 
the drug content in the film was cast uniformly or not. An increase in variation of weight 
and thickness of the film is indicative that drug distribution within the film is not uniform 
(Sabry, 2018). 
3.3.4.2.1 Sample preparation. 
The weight of the film was evaluated by weighing three films on a digital balancing 
scale and taking the mean weight as the weight of the film. The evaluation of film 
thickness was done by taking three films and measuring them for thickness using a 
micrometre screw gauge at three different places on the film. The mean value of the 
thickness of the films was used as the thickness of the film (Semalty, Semalty, & 
Kumar, 2008; Sabry, 2018).  
3.3.4.3 Folding endurance.  
The folding endurance of the film is done to illustrate the flexibility of the film. This 
flexibility shows that the film can be applied without it (the film) breaking (Karki et al., 
2016; Sabry, 2018).  
3.3.4.3.1 Sample preparation. 
The folding endurance of the films were determined by repeatedly folding the film at 
the same point until the film was broken. All folding tests were done in triplicates and 
the mean was taken as the final value for the folding endurance of the film. The folding 
endurance of the film is done to illustrate the flexibility of the films (Semalty et al., 
2008).  
3.3.4.4 Surface pH determination.  
It is important to assess the surface pH of the film, because a drastic change in pH 
which is significantly higher or lower than the physiological pH of the mouth 
(approximately 6.7 to 7.6) may cause the patient to experience tooth decay and 
irritation to the mucosa (Shaik et al., 2011).  A change in pH also influences the degree 
of hydration of the polymer chains, which affects the drug permeation and 
mucoadhesion of the film (Semalty et al., 2008, Sabry, 2018).  
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3.3.4.4.1 Sample preparation. 
The surface pH of the films was determined by cutting a small square (4 cm x 4 cm) 
of the film and exposing the film to 10 ml of distilled water at room temperature for 60 
min. The pH of the distilled water was first measured and recorded before the film was 
introduced to the water. After the 60 minutes time had been reached, the pH of the 
distilled water containing the film was measured using a pH meter (Semalty et al., 
2008).  
3.3.4.5 Swelling index. 
Hydration of the mucoadhesive film forming polymers allows them to expand and 
spread over the mucosa, thus starting the process of bioadhesion by initiating the 
interpenetration process between the mucin and the polymer chains. When the 
polymer swells, it exposes the bioadhesive sites on the film so that they are able to 
form non-covalent bonds such as electrostatic interactions and hydrogen bonds which 
are necessary to complete the process of bioadhesion between the polymer and the 
mucin networks (Semalty et al., 2008; Boddupalli, 2010; Muzib & Kumari, 2011; Sabry, 
2018). 
3.3.4.5.1 Sample preparation. 
The swelling Index tests were performed by cutting the films into a small square (2 cm 
x 2 cm). The cut film was then placed on a microscope glass slide which was pre-
weighed in order to determine the weight of the film itself. The glass slide containing 
the film was then weighed, where the difference between the two weights was the 
weight of the film. The glass slide was then placed into a petri dish containing 20 ml of 
a 0.1 M phosphate buffer solution which had a pH of 6.9 at a temperature of 37 ⁰C. 
The petri dish was then placed in an incubator at 37 ⁰C to maintain the temperature. 
The use of the phosphate buffer and the temperature was to mimic the conditions of 
the human mouth. The glass slide was removed from the petri dish every 15 minutes, 
then dried using filter paper and weighed to determine weight gain and weight loss of 
the film. The calculation used to determine the percentage of swelling is shown in 
Equation 6 (Semalty, Semalty, & Nautiyal, 2010; Sabry, 2018). 
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Equation 3.4: Showing the % swelling calculation (Semalty, 2010). 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 (%)
=
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑤𝑒𝑡 𝑓𝑖𝑙𝑚 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑖𝑛𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑦 𝑓𝑖𝑙𝑚
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑖𝑛𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑦 𝑓𝑖𝑙𝑚
 × 100 
 
3.3.4.6 Mechanical and physical properties. 
The mechanical properties of a film may be important as it gives information about the 
flexibility and strength of the film. A film with good mechanical properties is easily 
removed from the plate that it was cast on and easily rolled up. A film that is too flexible 
may become too elongated during cutting which may change the drug distribution 
within the film. This leads to the drug not being distributed uniformly within the film 
(Ikram, Gilhotra, & Gilhotra, 2015). The mechanical property that was tested on this 
film was the tensile strength. Tensile strength is the measure of the capacity of a 
material to withstand loads that tend to elongate the material and cause it to break 
(Satishbabu & Srinivasan, 2008). The tensile tests were done on six small discs of the 
film that were randomly punched out. The mucoadhesive film was gradually pulled by 
the load at a speed of 250 mm per minute. This allowed for the measurement of the 
ultimate tensile strength (UTS), which is a measurement of the maximum stress that 
the material is capable of withstanding before it breaks, as well as the thickness and 
width of the mucoadhesive film after the load was applied. Films were analysed for 
tensile strength using an MF longtravel extensometer at Aberdare Cables (Port 
Elizabeth)  
3.3.4.7 Drug release profile. 
It is essential to evaluate the drug release kinetics of the film because it is the rate 
limiting step in the absorption process. According to Morales and McConville (2011) 
the rate at which a drug is released from the polymer matrix of a film is dependent on 
the morphology and the physicochemical properties of the film. Drug release from a 
film is also influenced by the pH and temperature of the given environment. By varying 
the temperature and the pH of the environment for drug release studies, the diffusion 
of the drug from the film may be increased or decreased. It is believed that a drug is 
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released from a film once the film has eroded. For this to take place, the film needs to 
come into contact with biological fluids, in this case a phosphate buffer, which will 
cause the film to swell. Once the film swells, the polymer chains present in the film will 
relax thus releasing the drug from the polymer matrix. 
For the purpose of this research a franz diffusion cell (FDC) was used to assess the 
drug release kinetics of the film, as shown in Figure 3.7. An FDC is a type of in vitro 
permeation assay that is used to assess the diffusion of drugs from a dosage form. An 
FDC is made up of two compartments, namely the donor cell and the acceptor cell. 
The two compartments are separated by a semipermeable membrane that mimics the 
buccal mucosa. The donor cell is where the film to be tested is applied. This cell is 
placed on top of the semipermeable membrane. Below the membrane is where the 
acceptor cell is found. The acceptor cell was filled with a phosphate buffer with a pH 
of 6.9 at a constant temperature of 37 °C. This was the chamber that the samples for 
testing were taken from at regular intervals. The samples were taken from the acceptor 
cell for six hours. During the first hour, a sample was taken every 20 minutes and after 
that, a sample was taken every hour for the next 5 hours. Once a sample was taken 
from a acceptor cell, the same amount (as of sample taken out) was replaced with a 
phosphate buffer to maintain the quantity of the phosphate buffer within the acceptor 
cell. 
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Figure 3. 7: A graphical representation of a FDC (PermeGear, 2017) 
3.3.4.7.1 Sample preparation. 
500 µl of sample was taken from the sampling port of the FDC acceptor cell and placed 
into a beaker. 5 ml of methanol and 5 ml of ammonium acetate buffer were added to 
the beaker and stirred. The solution was then filtered through a syringe filter and 
placed into an HPLC vial for testing.  
3.3.4.7.2 Sample analysis.  
The percentage release of the drug from the mucoadhesive film was calculated by 
calculating how much drug was present in a 2 cm x 2 cm film. Using the linear 
calibration curve’s equation, the area under the peak that corresponds to the total drug 
in the 2 cm x 2 cm film was taken as the total peak area. The peak area obtained from 
the samples was used to calculate the percentage release using equation 3.5 below. 
The cumulative percentage release was calculated using an equation proposed by 
Chandrasekaran and colleagues stated below in Equation 3.6.  
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Equation 3.5: Percentage drug release from film 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (%) =  
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑓𝑟𝑜𝑚 𝑠𝑎𝑚𝑝𝑙𝑒
𝑇𝑜𝑡𝑎𝑙 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
 × 100 
 
Equation 3.6: Cumulative drug release calculation 
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (%)
= ቆ
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒 𝑤𝑖𝑡ℎ𝑑𝑟𝑤𝑎𝑛 (𝑚𝑙)
𝐵𝑎𝑡ℎ 𝑣𝑜𝑙𝑢𝑚𝑒 
 × 𝑃 (𝑡 − 1) + 𝑃𝑡ቇ  × 100 
Equation 3.6: the cumulative drug release calculation where Bath volume is the total 
volume of the acceptor cell (15 ml), P (t-1) is the percentage release previous to time 
‘t’ and Pt is the percentage release at the current time ‘t’ (Chandrasekaran et al., 2011). 
3.4 Statistical Analysis 
3.4.1 Statistical analysis: solubilisation of nystatin. 
Design-Expert software 7.00 was used to generate a table with the experimental runs 
to be performed (Table 3.1). The results were interpreted using a statistical software 
(Design-Expert software 7.0) and plotted on a ternary diagram also known as a 
simplex plot. The influence of the mixture components on the solubility of nystatin was 
determined statistically using analysis of variance (ANOVA). 
3.4.2 Statistical analysis: analytical method. 
All HPLC measurements were conducted in triplicates. All statistical analysis was 
conducted using Microsoft Excel® 2010 (Microsoft Corporation). The statistical 
analysis of the results involved calculating the mean values, the standard deviation 
(SD) and the relative standard deviations (RSD). Linearity was determined using linear 
regression analysis, with a correlation coefficient (R2) of greater than or equal to 0.999 
being an indication of acceptable linearity. 
3.4.3 Statistical analysis: polymeric micelle formulation. 
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Design-Expert software 7.00 was used to generate a table with the experimental runs 
to be performed (Table 3.2). The results were interpreted using a statistical software 
(Design-Expert software 7.0). The data was analysed using ANOVA analysis. A 
probability (p) value was calculated to show significance within the 95% confidence 
interval. If p < 0.05, this was defined as being significant. All other experiments were 
conducted in triplicates. 
3.4.4 Statistical analysis: mucoadhesive film. 
All tests were performed in triplicates. Data was captured using Microsoft Excel and 
descriptive statistics such as the mean, standard deviation and relative standard 
deviation calculated accordingly. Graphical representation of data was facilitated using 
Microsoft Excel. 
 3.5 Ethical Considerations  
No ethical clearance was needed for this study as there was no use of any human or 
animal samples in the study. This study was funded by the South African Department 
of Science and Technology. It should be noted that no conflict of interest existed during 
the course of the study. 
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CHAPTER 4 
Results and Discussions 
 
Pre-Formulations 
4.1 Nystatin Solubilisation 
The experimental runs were conducted and analysed for their responses. The 
response being evaluated was the quality of nystatin solubilisation which was 
represented using a grading system on a scale of 0 to 3. Grading 0 represents the 
experimental runs that did not solubilize at all, and even after being kept for three 
months at room temperature and at 4 °C fridge temperature, they still did not solubilize. 
Grading 1 represented experiments that took more than 10 minutes to solubilize 
nystatin initially but remained soluble, both at room temperature and at 4 °C fridge 
temperature after three months. Grading 2 meant that the mixture of the three solvents 
solubilized nystatin well initially, but after being kept at room temperature and at 4 °C 
fridge temperature for three months, only the experiments at room temperature 
remained without precipitation. Grading 3 meant that the mixture of the three solvents 
solubilized nystatin well and nystatin remained solubilized after being kept at room 
temperature and at 4 °C fridge temperature for three months.  
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Table 4. 1: The mixture components and the response to the mixture 
components using the grading system. 
Run Methanol (%) DMF (%) Water (%) Response of solubility  
(Grading) 
1 0 100 0 3 
2 16.667 66.667 16.667 3 
3 50.00 0.00 50.00 0 
4 50.00 50.00 0.00 3 
5 0.00 0.00 100.00 0 
6 100.00 0.00 0.00 0 
7 0.00 0.00 100.00 0 
8 50.000 50.00 0.00 3 
9 100.00 0.00 0.00 0 
10 66.667 16.667 16.667 1 
11 0.00 50.00 50.00 3 
12 16.667 16.667 66.667 1 
13 0.00 100.00 0.00 3 
14 33.333 33.333 33.33 1 
Keys to grading  
0 – Does not solubilize nystatin  
1 – Takes more than 10 minutes to solubilize 
2 – Dissolves only at room temperature  
3 – Dissolves at both room temperature and at 4 °C 
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4.1.1 ANOVA analysis of nystatin dissolution. 
The ANOVA analysis was used to assess how well the chosen model (quadratic 
model) fits the response variables using the F-value and the p-value. The F-value and 
p-value in an ANOVA analysis give an indication of the significance of the data. A 
small p-value of less than 0.05 and a large F-value indicate that that the model is 
significant (Varanda, Portugal, Ribeiro, Silva, & Silva, 2017). In the ANOVA analysis 
presented in Table 4.2, it can be seen that the model, linear mixture components, AB, 
BC and ABC are significant model terms; with A being DMF, B being methanol and C 
being water. This is illustrated with a high F-value and low p-value of less than 0.05. 
These results mean that the model could be used to evaluate the design space. 
Table 4. 2: ANOVA data for nystatin solubilisation. 
Terms Investigated  F-Value p-value Significance 
Model 164.47 0.0001 Significant 
Linear Mixture 403.92 0.0001 Significant 
AB 120.21 0.0001 Significant 
AC 0.063 0.8087 Non-significant 
BC 77.24 0.0001 Significant 
ABC 38.92 0.0004 Significant 
    Keys  
- A = DMF 
- B = methanol  
- C = water 
4.1.2 Diagnostics plot. 
Diagnostic plots are used to assess how the data fits the model. The diagnostic tools 
used in this experiment were the normal plot of residuals plot, and the predicted versus 
actual plot. 
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4.1.2.1 Normal plot of residuals. 
The normal plot of residuals is a graphical technique used to evaluate whether a data 
set is normally distributed. This is done by identifying outliers and validating the 
normality of the experimental errors. The data set to be investigated is plotted against 
a theoretical normal distribution (shown as the diagonal line). In the ideal normal plot 
of residuals, the data set points would follow a straight line along the diagonal line; 
however some moderate scatter is expected. Data set points that are not 
appproximately linear, and show an s-shaped curve demonstrate a non-normality in 
distribution (State-Ease, 2018).  
 
The normal plot of residual for nystatin dissolution is illustrated in Figure 4.1. Figure 
4.1 does not show an S-shaped curve and the data points are set close to the diagonal 
line. This shows a normal distribution of residuals. 
 
 
Figure 4. 1: Normal plot of residuals for nystatin dissolutio 
4.1.2.2 Predicted versus actual. 
The predicted vs actual plot is a graph of the predicted response values versus the 
actual response values obtained. This graphical technique is used to identify data sets 
that may not be easily predicted by the statistical model. For the data set to be 
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considered to have a good fit, it needs to be closely fitted onto the diagonal line. The 
diagonal line represents the predicted data set. Points that are further away from the 
diagonal line indicate that those data sets are outliers (Stat-Ease Inc, 2018). A plot of 
predicted vs Actual for nystatin dissolution is illustrated in Figure 4.2. The data sets 
are found closely fitted around the solid diagonal line. This indicates that the data set 
for nystatin dissolution fits the model design well.  
 
Figure 4. 2: Predicted vs actual Plot 
4.1.3 Response surface plots. 
To better illustrate the results obtained from the grading of nystatin solubilisation, a 
visual three-dimensional response surface plot is shown in Figure 4.3. The red areas 
represent areas that would solubilise nystatin to a grading of three; the yellow areas 
show a grading of 2; the green areas show a grading of 1; and the blue areas show a 
grading of 0. The plot shows that DMF is essential for nystatin solubilisation, when les 
DMF is added to the mixture, nystatin solubility decreases. This is shown visually, 
where the areas away from point B lose their red shading and change colour. It was 
observed that nystatin was only soluble in the presence of DMF. This was evident from 
the plot as Point B was coloured in red. In experimental runs where DMF was not 
included as a solvent, nystatin did not solubilise. This was interpreted from the plot, as 
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point A and C had a deep blue colour showing that water and methanol alone could 
not solubilise nystatin.  
4.2 Analytical Method Development 
4.2.1  Linearity. 
The method was tested for linearity using six different concentrations (200 %, 150 %, 
100 %, 75 %, 50 %, 25 %). A calibration curve was created using Microsoft excel to 
plot a graph (illustrated in Figure 4.4) of the area under the curve versus nystatin 
concentration using Table 4.3. The plot was used to determine the correlation 
coefficient (R2). According to Green (1996), the acceptable range for R2 is greater than 
or equal to 0.999. The R2 for this method was found to be 0.997. Although this value 
does not equal 0.999, it is still acceptable. This was based on an experiment 
conducted by Hussien (2014), where the R2 was found to be 0.997 and was 
considered acceptable. The author believed that an R2 of 0.997 is able to show 
correlation between the area under the peak and the concentration of the samples.  
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The linear regression equation for the concentration range of 25% to 200% resulted in 
y = 332763x – 55715. This equation was used to calculate the z value (Equation 3.1). 
This resulted in a z value of -0.168, which is between the range of -2 and 2 and is 
therefore acceptable. The %RSD calculated for the different concentrations were all 
below or equal to 1.91%. The results from the data show that the analytical method is 
indeed linear. 
Table 4. 3: Calibration data used for the analysis of the analytical method used 
for the pre-formulation studies of nystatin 
Concentration (%) Mean peak area (n=3) % RSD 
25 % 41881,67 1,91 % 
50 % 97763,45 0,39 % 
75 % 184706,42 1,84 % 
100 % 275096,36 1,03 % 
150 % 458492,55 0,15 % 
200 % 604343,92 1,30 % 
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Z value calculation  
Z value = (-55715 / 33 220 585) x 100 
Z value = -0.168 
4.2.2 Accuracy. 
Table 4.4 shows the concentrations that were investigated and their percentage 
recovery. Accuracy of the analytical method was acceptable because all the 
concentrations tested gave a percentage recovery of between 98 % and 102 % range. 
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Figure 4. 4: A calibration curve showing mean peak area vs nystatin 
concentration. y = 332763x – 55715; R2 = 0.997. 
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Table 4. 4: Accuracy data for the pre-formulation studies of nystatin 
 
 
Theoretical value Measured mean area 
under peak (n=3) 
% Recovery 
25 % 41881 41912,00 100 % 
100 % 275096,4 271516,92 99 % 
150 % 458492,5 468777,55 102 % 
  
4.2.3 Precision. 
Table 4.5 represents the data obtained from the precision validation. The precision for 
the analytical method was within the accepted range, as the %RSD of all the samples 
taken from each vial was lower than 2. 
Table 4. 5: Precision data for the pre-formulation studies of nystatin 
Vial 
number 
mean peak area (n=3) SD RSD (%) 
1 357311 6024,59 1,69 % 
2 354005,7 6591,09 1,86 % 
3 358715,7 905,242 0,25 % 
4 361094 6784,385 1,88 % 
5 368152,7 1017,633 0,28% 
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4.2.4  Specificity. 
The purity index of the contaminated sample showed that there were no impurities 
detected as can be seen in figure 4.5. This shows that the method is specific for the 
detection of nystatin. Figure 4.6 illustrates an analyte that contains nystatin and Figure 
4.7 shows an analyte that had no addition of nystatin. As can be seen from Figure 4.7, 
there was no peak at time 3.25 minutes as would be expected if nystatin was present. 
This was interpreted to mean that the solvents that nystatin was solubilised in and the 
mobile phase were not the peak that was seen at time of 3.25 minutes as nystatin. 
 
Figure 4. 5: A diagram showing the purity curve of nystatin in the presence of 
poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) 
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Figure 4. 6: A chromatogram showing a peak for nystatin reading in the 
presence of poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide)  
 
 
Figure 4. 7: A chromatogram showing the results of an analyte without nystatin 
present 
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4.3 Polymeric Micelles Formation and Characterisation 
4.3.1 Statistical analysis of data. 
Each experimental run was conducted in the laboratory and analysed for five 
responses. The responses that were being evaluated were mean particle size, mean 
PDI, mean zeta potential, change in mean particle size and change in mean PDI which 
were evaluated two weeks after the micelles were initially formed. The design model 
which best suited the responses was the quadratic design. The model was evaluated 
using ANOVA analysis and diagnosed using the normal plots of residuals. The 
responses were then further illustrated using three-dimensional response surface 
plots. 
4.3.1.1 Statistical Evaluation of mean particle size.  
4.3.1.1.1 ANOVA analysis of mean particle size. 
The ANOVA analysis for mean particle size is shown in Table 4.6. Table 4.6 illustrates 
that the model and the terms B, A2, B2 are significant model terms. This is evidenced 
by a large F-value and a low p-value of less than 0.05; with model term A being the 
temperature of the hydration medium and B being the rotary evaporation time. Term 
A was shown to be non-significant as was evidenced by the p-value greater than 0.05. 
The results indicate that the temperature of the hydration water added alone did not 
influence the mean particle size and the model could be used to evaluate the design 
space. 
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Table 4. 6: ANOVA analysis of mean particle size 
Terms Investigated  F-Value p-value Significance 
 Model 5.09 0.0248 Significant 
A-Temperature 2.58 0.1472 Non-significant 
B-Rotary 
evaporation time 
5.81 0.0425 Significant 
A2 5.42 0.0482 Significant  
B2 8.06 0.0218 Significant 
4.3.1.1.2 Statistical diagnosis of mean particle size.  
The quadratic model was evaluated to assess if the data set was quadratic when using 
a normal plot of residuals. The data points on the normal plot of residuals should be 
approximately linear following the diagonal trend line. A non-linear pattern, such as an 
s-shaped curve implies that there is non-normality in the error term. Figure 4.8 is the 
normal plot of residual of mean particle size. As can be seen in figure 4.8, there is an 
s-shaped curvature present (circled in red). This means that there is a non-normality 
in the error term. This implies that the experimental data do not behave as predicted 
by the statistical model. 
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Figure 4. 8: The normal plot of residual of mean particle size. The red circle 
shows the s-shaped curvature. 
4.3.1.1.3  Response surface plot analysis of mean particle size.  
A three-dimensional response surface plot was used to aid in visualizing the 
relationship between the factors and the response. Figure 4.9 represents the 
relationship between the two factors and the mean particle size. The areas that are 
shaded in blue indicate that at short rotary evaporation time and at temperatures 
between 32.5 ⁰C to 40 ⁰C, the micelles had a mean particle size of 46.09. The figure 
also shows that the longer the micelles are exposed to the conditions of the rotary 
evaporator, the larger the mean particle size becomes irrespective of the hydration 
temperature. This is shown as the areas of the response surface plot that are shaded 
in red.  
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Figure 4. 9: Response surface plot of mean particle size 
4.3.1.2 Statistical Analysis of mean PDI. 
4.3.1.2.1 ANOVA analysis of mean PDI. 
The ANOVA analysis of the mean PDI is shown in Table 4.7. The model and terms B, 
AB, A2 were not significant. This was due to the terms having a large p-value of greater 
than 0.05. Term B2 was significant as it had a p-value of less than 0.05. This shows 
that only model term B2 was significant; with model term A being the temperature of 
the hydration medium and B being the rotary evaporation time. 
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Table 4. 7: ANOVA analysis of mean PDI 
Terms Investigated  F-Value p-value Significance 
 Model 3.14 0.1026 Non-significant 
B-Rotatory 
evaporation time 
1.04 0.3482 Non-significant 
AB 1.26 0.3043 Non-significant 
A2 3.14 0.1269  Non-significant 
B2 10.90 0.0164 Significant  
 
4.3.1.2.2 Statistical diagnosis of mean PDI. 
Figure 4.10 shows the normal plot residuals of mean PDI. There is no s-shaped 
curvature present and the data sets are close to the linear line. This means that the 
data set has a normal distribution. 
 
Figure 4. 10: The Normal plot of residuals of mean PDI. 
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4.3.1.2.3 Response surface plot analysis of mean PDI. 
Figure 4.11 represents the response surface plot showing a relationship between the 
two factors and the mean PDI. The response surface plot shows that when the polymer 
solution was exposed to low hydration temperature (30 ⁰C) and a shorter time (90 min) 
within the rotary evaporation environment, the mean PDI was higher at approximately 
0.208. This is indicated by the red shaded areas. According to Figure 4.11 the mean 
PDI was lower when exposed to hydration temperatures of between 32 ⁰C and 37 ⁰C 
and at a rotary evaporation time of between 112.50 minutes and 157.50 minutes. The 
results indicate that rotary evaporation time had an effect on the PDI of the micellar 
system. 
 
 
Figure 4. 11: Response surface plot of mean PDI 
4.3.1.3 Statistical Analysis of mean zeta potential.  
4.3.1.3.1 ANOVA analysis of mean Zeta potential. 
The ANOVA analysis of the mean zeta potential is shown in Table 4.8. The model and 
term B2 were shown to be significant. This is due to their large F-value and their small 
p-value; that is less than 0.0500. This means that the other model terms, such as 
temperature of hydration medium added and rotary evaporation time, did not have a 
significant effect on the zeta potential of the micelles.  
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Table 4. 8: ANOVA analysis of mean zeta potential 
Terms Investigated  F-Value p-value Significance 
 Model 4.53 0.0397 Significant  
A-Temperature 0.91 0.3619 Non-significant 
B2 8.15 0.0171  Significant 
 
4.3.1.3.2 Statistical diagnosis of mean zeta potential. 
Figure 4.12 represents the normal plot of residual of the mean zeta potential. There 
are no s-shaped curvatures seen on the plot and all the data points are close to the 
linear line. This means that the data set has a normal distribution. 
 
Figure 4. 12: Normal plot of residuals of the mean zeta potential 
4.3.1.3.3 Response surface plot analysis of mean zeta potential. 
Figure 4.13 represents the relationship between the two factors and the mean zeta 
potential. According to the surface response diagram indicating hydration temperature 
did not have an impact in changing the mean zeta potential. However, the length of 
time at which the micelles were exposed to the rotary evaporator, had an impact on 
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the change in mean zeta potential. The mean zeta potentials were mostly negative as 
shown by a large area being shaded in blue. A negative zeta potential indicates that 
the micelles had a negative charge.   
 
 
Figure 4. 13: Response surface plot of mean zeta potential 
4.3.1.4 Statistical analysis of change in mean particle size.  
4.3.1.4.1 ANOVA analysis of change in mean particle size.  
The ANOVA analysis of the change in mean particle size is shown in Table 4.9. The 
model and the terms B and B2 were found to be significant because they had a large 
F-value and a low p-value of lower than 0.0500. This means that the temperature of 
water added did not have a significant effect on the change in size; with model term A 
being the temperature of the hydration medium and B being the rotary evaporation 
time. 
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Table 4. 9: ANOVA analysis of Change in mean particle size 
Terms Investigated  F-Value p-value Significance 
 Model 5.78 0.0199 Significant 
A-Temperature  5.089 0.9826 Non-significant 
B-Evaporation time 18.29 0.0037 Significant 
AB 1.13 0.3225 Non-significant 
A2 1.49 0.2619 Non-significant 
B2 6.97 0.0334 Significant 
4.3.1.4.2 Statistical diagnosis of change in mean particle size. 
Figure 4.14 represents the normal plot of residual of change in mean particle size. 
There were no s-shaped curvatures seen on any of the plots and all the data points 
were close to the linear line. This means that the data set has a normal distribution. 
 
Figure 4. 14: Normal plot of residuals of change in mean particle size 
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4.3.1.4.3 Response surface plot analysis of change in mean particle size. 
Figure 4.15 illustrates the relationship of the two factors and the change in mean 
particle size. As shown in Figure 4.15 the change in particle size was mostly small, 
this is shown by most of the area on the response surface plot being shaded in red. 
The red shading indicates that the change in mean particle size was 0.08. This shows 
that there was not much difference in the size of the micelles after it had been kept for 
two weeks. This indicates that the micelles are stable. This indicates that the micelles 
were stable enough not to aggregate together 
 
 
Figure 4. 15: Response surface plot of change in mean particle size 
4.3.1.5 Statistical analysis of change in mean PDI. 
4.3.1.5.1 ANOVA analysis of change in mean PDI. 
The ANOVA analysis of the mean change in PDI is shown in Table 4.10. The model 
and all terms investigated were not significant. This was evident from all of them having 
a high p-level above 0.0500. This means that none of the model terms had a significant 
effect on the change in PDI.  
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Table 4. 10: ANOVA analysis of change in mean PDI 
Terms Investigated  F-Value p-value Significance  
 Model 1.60 0.2905 Non-significant 
A-Temperature  0.44 0.5336 Non-significant 
B-Evaporation time 3.22 0.1227 Non-significant 
AB 0.66 0.4476 Non-significant 
A2 0.91 0.3777 Non-significant 
B2 2.01 0.2001 Non-significant 
 
4.3.1.5.2 Statistical diagnosis of change in mean PDI. 
Figure 4.16 represents the normal residual plot of change in mean PDI. No s-shaped 
curvatures were identified on the plot. All the data points are close to the linear line 
meaning that the data set has a normal distribution. 
 
Figure 4. 16: The normal plot of residuals of change in mean PDI. 
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4.3.1.5.3 Response surface plot analysis of change in mean PDI.  
Figure 4.17 illustrates the relationship between the two factors and change in mean 
PDI. The three-dimensional response surface plot shows that the change in mean PDI 
was well distributed. The change ranged from 0.013 to -0.116. The mean change in 
PDI leaned closer to the 0.013 value. This is indicated by having most of the plot area 
being shaded in red, yellow and green. This means that the change in mean PDI was 
very small and that even after the micelle solution was kept for two weeks, it was still 
well distributed within the solution. 
 
 
Figure 4. 17: Response surface plot of change in mean PDI 
4.3.1.5 Point prediction of optimal values  
Point prediction uses the information obtained from the model fit analysis to predict 
what the responses would be for the optimal micelles (Stat-Ease Inc, 2018). It was 
observed from the statistical data that the longer the rotary evaporation time, the larger 
the mean particle size of the micelles. Temperature of hydration water added did not 
seem to have any effect on the size, PDI or zeta potential of the micelles. This means 
that other factors such as the solvent composition should have also been taken into 
consideration while forming the micelles. Once the optimal response was established, 
the operating conditions were used to form the optimal micelles. These were done in 
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triplicates, and the mean responses were taken and compared to the predicted 
responses. The optimal operating conditions were a rotary evaporation time of 180 
minutes and a temperature of water of 30 °C. Design Expert does not only give a 
predicted value; but low and high values at a 95 % confidence interval (CI) in which 
the expected response values of the runs may be in. 
There were significant inconsistencies seen with the experimental results which may 
have caused the failure of the predicted model to fit the experimental results. This can 
be seen in Table 4.11 where the responses for mean particle size and mean PDI fall 
within the predicted range. The response for change in mean PDI did not fall within 
the predicted range; it is off by a very low value of 0.002. The mean zeta potential and 
the change in mean particle size did not fit in range of the predicted values. This is 
also evident in the p-values that did not seem to fit well. A common problem associated 
with the production of nanoparticles, that may have also contributed to the 
inconsistencies, is maintaining a batch-to-batch reproducibility of the micelles. This 
may have been overcome by adding more experimental runs.   
Table 4. 11: The predicted response versus the actual response of the optimal 
micelles 
Response Prediction  95% low (CI) 95% high (CI) Actual 
Mean particle size 58.5712 51.41 65.73 63.26 
Mean PDI 0.15 0.091 0.21 0.164 
Mean Zeta potential 1.296 -1.82 7.41 -8 
Change in mean 
particle size 
-6.5688 -9.06 -4.07 -0.715 
Change in mean PDI -0.059 -0.10 -0.016 0.018 
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4.3.2  Micelle characterization. 
4.3.2.1 Size and zeta potential. 
Figure 4.18 shows the hydrodynamic size distribution of the micelles within the micelle 
solution. The results were obtained from doing triplicate runs of the micelle solution 
using the Malvern ZS nano Zetasizer. The mean hydrodynamic size of the polymeric 
micelles was found to be 78.98 nm. This is within the acceptable size range. According 
to Wang and colleagues (2005), micelles should be no larger than 100 nm thus 78.98 
nm is still within the size range of micelles (Wang, Mongayt, & Torchilin, 2005). The 
mean PDI, which indicates the extent of size distribution of the micelles within a 
solution, was found to be at 0,266. This indicates that there was a moderate 
distribution of the particle size and that the solution was moderately homogeneous 
(Alonso & Csaba, 2012).  
 
Figure 4. 18: The hydrodynamic size distribution plot of the polymeric micelles 
Figure 4.19 illustrates the phase plot of the zeta potential of the polymeric micelle 
solution. The mean zeta potential of the micelles was found to be -9.1 mV. This 
indicated that the micelle solution had a weak negative charge. A small negative 
charge indicates that the micelle solution has a weak repulsive force which prevents 
them from aggregating. Although -9.1 mV is considered as a zeta potential that is 
associated with an unstable micellar solution, this is not the case. The zeta potential 
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was low because the polymer used in micelle formation did not have a high charge, 
therefore the micellar solution would also not have a high charge. This means that the 
micellar solution was stable with no aggregation of the micelles seen even after 2 
weeks of being kept at -4 °C. 
 
 
Figure 4. 19: Phase plot of the zeta potential of the polymeric micelles  
4.3.2.2 Atomic force microscopy. 
Figure 4.20 shows the three-dimensional image of the micelles with the lighter parts 
being the most elevated parts of the micelles. Figure 4.21 shows the two-dimensional 
image of the micelles with the measurement of one of the micelles. The lighter parts 
of the image indicates the presence of a micelle (the white oval shapes). The AFM 
determined that the micelles had a spherical shape with a diameter ranging from 68.4 
nm to 98.6 nm and a hydrodynamic size of 78.98, just as predicted by literature.  
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Figure 4. 20: Three-dimensional view polymeric micelle using AFM imaging 
 
 
Figure 4. 21: Two-dimensional image of polymeric micelle  
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4.3.2.3 Transmission electron microscopy. 
The TEM image seen in Figure 4.22 confirms what was seen in the AFM. The TEM 
images show that the polymeric micelles are spherical in shape, and the size of the 
micelles ranged from 60 nm to 105 nm. This shows that the size is still within the 
nanometer range and that there is a narrow size distribution of the micelles. 
 
Figure 4. 22: TEM images showing nystatin encapsulated micelles 
4.3.2.4 Micelle drug encapsulation. 
The initial amount of drug introduced for micelle encapsulation was 10 mg. Using the 
calibration curve from the HPLC linearity validation, the amount of drug encapsulated 
within the micelles was quantified to be 3.6 mg. This resulted in the drug encapsulation 
efficiency being 36%. This means that nystatin was not encapsulated effectively, 
because less than 50% of the drug was encapsulated. This could be due to the amount 
of block co-polymer that was used for micelle formation being of small quantity. Drug 
encapsulation may be improved by increasing the amount of polymer solubilized for 
micelle formation. Figure 4.23 is a TEM image that shows the micelles encapsulating 
nystatin. The red circle shows the micelles, and the red arrow is pointing to the 
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encapsulated nystatin. The blue arrow is showing the free nystatin that was not 
encapsulated (the free floating small black dots).  
 
Figure 4. 23: TEM image showing drug micelle encapsulation of nystatin 
4.4 Mucoadhesive Film Characterisation 
4.4.1 Film characterization. 
4.4.1.1 Surface smoothness and physical appearance. 
The surface smoothness of the films was evaluated visually and through touch, to see 
if there were any inconsistencies or bumps. The HPMC film appeared clear and 
colorless. It was also smooth to the touch, with no visible bumps or bubbles on the 
surface. This shows that the film has a good physical appearance. Such 
characteristics are highly patient acceptable (Boddupalli et al., 2010). Figure 4.24 
shows physical appearance of the HPMC film. The SCMC film was smooth to the 
touch with no visible bumps or bubbles on the surface. However, the film had a cloudy 
white colour which may not be patient acceptable as patients do not prefer products 
that may discolour their tongue (Rossiter, 2012). 
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Figure 4. 24: HPMC mucoadhesive film 
4.4.1.2  Folding endurance. 
Film pliability was tested using the folding test. The HPMC films were folded at the 
same place over 300 times, and this was taken as the end point. The film did not show 
any signs of breaking or damage. This means that the film is highly pliable and will not 
break while being handled. The SCMC films were folded at the same place and broke 
after being folded 10 times. This means that the film was not pliable and breaks easily; 
this is illustrated in Figure 4.25 where the film could not be lifted out of the petri dish 
that it was cast in without breaking. A film that demonstrates low pliability is not 
preferred by patients, because it may break while it is being handled by a patient. Due 
to the SCMC film breaking easily, the HPMC film was taken as the superior film and 
no further characterization was conducted on the SCMC film. 
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Figure 4. 25: The Sodium Carboxymethylcellulose film with a cloudy white 
colour  
The film was found to have low pliability as is evident from the film tearing while being 
lifted out of the petri dish. 
4.4.1.3 Film weight and thickness. 
The mean HPMC film weight was 483,37 mg and the average film thickness was 0.087 
µm. The film thickness was consistent throughout the three films tested, with a relative 
standard deviation of 6.6%. The consistent film thickness and weight shows that the 
drug within the film is evenly distributed, as there are no areas of the film that are 
significantly thicker than others. This meant that there are no areas of the film with a 
higher drug concentration than the other areas. 
4.4.1.4  Surface pH determination. 
The mean surface pH for HPMC film was determined to be 7.29, which is within 
the pH range of the mouth. This means that the film will not cause irritation to the 
mucosa while it is being applied for treatment. 
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4.4.1.5  Swelling Index. 
The HPMC film was able to swell to a maximum of 550%. This was noted after 30 
minutes of exposing the film to a phosphate buffer at a temperature of 37 °C. This 
means that the film can easily spread over the mucosa for adhesion. This is illustrated 
graphically in Figure 4.26. The non-linear regression line was added using Microsoft 
Excel and had an equation of y = 3.0383ln(x) + 0.2264 with a R2 value of 0.97. 
  
Figure 4. 26: Percentage swelling vs time graph, showing the percentage 
swelling of the film at specific times 
The non-linear equation for the graph is y = 3.0383ln(x) + 0.2264 with a R2 value of 
0.97. 
4.4.1.6 Mechanical and physical properties. 
Mechanical testing was repeated six times. The force that was used to break the 
HPMC films was determined by measuring the weight of the load that caused the 
breakage (Satishbabu & Srinivasan, 2008). The mean ultimate tensile strength ( UTS) 
of the samples was 16.5 MPa, with a RSD of 24 %. The mean maximum load applied 
to cause a fracture was 5,098 N with a RSD of 22.7 %. The mean thickness after the 
load was applied was 0,082 mm with a RSD of 10 % and the mean width after the load 
was applied was 3,817 mm with an RSD of 7.2 %. These results are presented in table 
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4.12. The results show that the film has a high tensile strength with a low chance of 
elongation. This is evident when the width of the film, after a load has been applied, is 
compared to the width of the film before the load was applied and it (the width) is 
almost unchanged. This means that the film has good mechanical properties. A good 
mucoadhesive film should be strong and flexible. The film in this research meets 
thiscriteria (Bahri-Najafi, Tavakoli, Senemar, & Peikanpour, 2014).   
Table 4. 12: Mechanical test results 
 
4.4.1.7  Drug release profile. 
In-vitro release studies were conducted using the FDC. The results are presented in 
Figure 4.27. Figure 4.27 illustrates that most of the drug is released from the HPMC 
film within the first 60 minutes after the film has been exposed to the FDC system. 
Although most of the drug is released within the first 60 minutes, this is not of concern 
as nystatin exhibits a post-fungal effect; thus nystatin will be showing antifungal activity 
even after the hour when most of the drug has been released (Gunderson et al., 2000). 
The film is also not intended to be in the mouth for a long period of time (greater than 
4 hours), as this would interfere with normal oral functions such as eating and drinking. 
It is therefore an advantage that most of the drug is released in the first hour. In order 
Name UTS (MPa) Load @ MAX (N) Thickness 
(mm) 
Width (mm) 
Test Run 1 15,9 4,917 0,080 3,870 
Test Run 2 16,4 5,289 0,080 4,020 
Test Run 3 10,0 3,225 0,080 4,040 
Test Run 4 15,2 4,721 0,090 3,440 
Test Run 5 20,3 5,737 0,070 4,030 
Test Run 6 21,3 6,702 0,090 3,500 
Mean 16,5 5,098 0,082 3,817 
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to prevent have better drug release control perhaps a different mucoadhesive polymer 
should be used instead of the polymer investigated. The drug  might have been 
released quickly due to the polymer which may not have been compatible with nystatin 
 
Figure 4. 27: Drug release rate from mucoadhesive film 
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CHAPTER 5 
Conclusion and Recommendation 
5.1 Conclusion and Recommendations for Further Studies 
5.1.1 Conclusion. 
This study aimed to improve drug delivery of nystatin for the treatment of oral thrush, 
by developing a nystatin loaded micellar system to be incorporated into a 
mucoadhesive film for drug delivery. This was achieved by using the statistical 
software Design Expert to create a mixture design (the simplex lattice design), to allow 
for an appropriate solvent system for the solubilization of nystatin to be established. 
The model selected by the statistical software for the solubilisation system of nystatin 
proved to be effective and nystatin was successfully solubilised. According to the 
statistics software, nystatin may be solubilised using a mixture of methanol, water and 
DMF. It was observed that the presence of DMF was necessary for nystatin 
solubilisation. 
Design Expert was also used for the statistical optimization of the nystatin 
encapsulated polymeric micelles using the CCRD design. The design recommended 
for the polymeric micelles was a challenge, because not all the responses were 
accurately predicted by the statistical model. This may have been due to batch to batch 
inconsistencies associated with nanoparticle synthesis and formation. 
Once the micelles were formed, they were characterised for size, stability, morphology 
and drug encapsulation efficiency. Characterisation for size showed that the micelles 
were all within an acceptable size range. They were moderately distributed within the 
micelle solution. The micelles were also found to be stable, despite their zeta potential 
being low. This was evidenced by the small change in size, after the micelles had been 
kept at 4 ⁰C for two weeks. Morphology of the micelles was investigated using AFM 
and TEM. Both instruments illustrated that the micelles were spherical in shape and 
all were within the appropriate size range. The drug encapsulation efficiency of the 
micelles was low; only encapsulating 36% of nystatin. This may have been due to the 
amount of polymer used for encapsulation being too little. 
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The nystatin encapsulated micelles were incorporated into a mucoadhesive film which 
was cast using the solvent casting method. Two films, with two different polymers 
(HPMC and SCMC) were investigated. The two films were characterised for physical 
appearance and pliability. The HPMC film was found to be superior and was 
characterised for film weight and thickness, mechanical properties, swelling index and 
drug release profile. The HPMC film had a patient acceptable physical appearance 
and feel. The film was found to be pliable, and it had a consistent thickness and weight. 
The mechanical properties of the film were acceptable, as it exhibited strength and 
flexibility. The swelling index test was done to investigate how well the film could 
spread over the mucosa. The film was found to swell 550% of its initial weight, 
indicating that it can easily spread over the mucosa. Drug release profile was 
investigated using the Franz diffusion cells. 62.5% of the drug was released within 60 
minutes. This shows that the drug has a controlled release. 
The aim of this research was to develop a buccal mucoadhesive film containing 
nystatin encapsulated in a polymeric micelle. This is proposed for the treatment of 
oropharyngeal candidiasis in children and chronically ill patients. The proposed buccal 
mucoadhesive film is a major need because (1) there is an increase in OPC infections 
in recent years and (2) the mechanism of application of the current OPC treatment 
(nystatin suspension) is not patient friendly, as it needs to be applied often because 
the suspension does not adhere to the affected area. Based on the major findings of 
this study, a nystatin loaded micellar system was successfully developed and 
incorporated into a mucoadhesive film.  
These are the first steps in the journey to creating novel delivery systems for the 
treatment of common diseases, and there are still many challenges to overcome 
before this novel product can appear in the market. The first problem that must still be 
addressed stems from batch to batch variability of the micelles, because this 
contributes to an unknown amount of drug being encapsulated in each micelle, and 
size variation of each micelle. Secondly, the effectiveness of the nystatin film is still 
unknown, as this was not tested in this study. This leaves room for future studies of 
this nature; to investigate if the dose used and the drug release rate is sufficient to 
effectively kill OPC causing microorganisms. Another important aspect that should be 
investigated with regards to the effectiveness of nystatin is the minimal time the film 
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should be in contact with the affected area, and the minimal concentration to be 
entrapped in the micelle to effectively kill the oropharyngeal causing microorganisms. 
This is because nystatin is a concentration dependant antifungal agent and not a time 
dependant antifungal agent. It is crucial that attention is also given to the affordability 
of this novel system, which aims to make the treatment of OPC easier, as OPC is a 
condition more common in immune compromised patients who may already be 
struggling with medical costs. Studies on cost effective ways of developing novel drug 
delivery systems, that have proven to work, should be conducted.  The development 
of more effective delivery systems such as that proposed in this study, will (1) 
encourage patient compliance, (2) decrease recurrence of OPC and (3) will make it 
easier for caregivers to administer OPC treatment to patients thus improving the 
treatment outcomes. 
5.1.2 Recommendation. 
Some of the challenges encountered in this study was batch to batch variability and 
drug entrapment efficiency. This problem may perhaps be solved by using a larger 
quantity of polymer when forming the micelles. The researcher recommends clinical 
testing to be conducted, to determine the effectiveness of the film and its antifungal 
properties. More physical testing should be conducted on the film, to determine the 
storage conditions of the film.   
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